```
=> b reg
FILE 'REGISTRY' ENTERED AT 15:42:36 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAY 2008  HIGHEST RN 1020256-26-1
DICTIONARY FILE UPDATES:  11 MAY 2008  HIGHEST RN 1020256-26-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l16
L12      408602 SEA FILE=REGISTRY ABB=ON  PLU=ON  >=2 46.150.18/RID AND
                46.156.1/RID
L14              STR
```




```
VAR G1=AK/ID
VAR G2=O/S
VAR G3=6-3 7-5/10-3 9-5
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E5 C  E1 N  AT   1
ECOUNT  IS E6 C  AT   2
ECOUNT  IS E6 C  AT   5

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L16         860 SEA FILE=REGISTRY SUB=L12 SSS FUL L14

100.0% PROCESSED  408602 ITERATIONS                          860 ANSWERS
SEARCH TIME: 00.00.03



=> b hcao
FILE 'HCAOLD' ENTERED AT 15:42:56 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate
substance identification.  Title keywords, authors, patent
assignees, and patent information, e.g., patent numbers, are
now searchable from 1907-1966.  TIFF images of CA abstracts
printed between 1907-1966 are available in the PAGE
```

display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of
all substance data from the REGISTRY file. Enter HELP FIRST for
more information.

=> d all l28 tot

L28 ANSWER 1 OF 1 HCAOLD COPYRIGHT 2008 ACS on STN
AN CA53:5932e CAOLD
TI benzoylacetanilide (substituted) color couplers
PA Imperial Chemical Industries Ltd.
DT Patent
TI substituted benzoylacetanilide color couplers
AU Corby, Neville S.; Haddock, N. H.
DT Patent

PATENT NO.	KIND	DATE
DE-----1080399		

PI GB------805505
IT 858-02-6 101575-50-2 101585-92-6 101879-13-4 102016-31-9
102157-71-1 102701-37-1 103390-36-9 103402-24-0 103510-23-2
105905-00-8 105905-01-9 109396-22-7 112116-95-7 124140-60-9

```
=> b reg
FILE 'REGISTRY' ENTERED AT 15:43:07 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAY 2008  HIGHEST RN 1020256-26-1
DICTIONARY FILE UPDATES:  11 MAY 2008  HIGHEST RN 1020256-26-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d ide can l29 tot
```

L29 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 103402-24-0 REGISTRY
ED Entered STN: 26 Jul 1986
CN Benzoic acid, 4-(methyloctadecylamino)-3-(2-p-piperidinobenzoylacetamido)-
(6CI) (CA INDEX NAME)
MF C40 H61 N3 O4
SR CAOLD
LC STN Files: CA, CAOLD, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 53:33464

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 15:43:25 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 May 2008  VOL 148 ISS 20
FILE LAST UPDATED: 11 May 2008  (20080511/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitrn fhitstr l19 tot
```

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:902353 HCAPLUS
DN 141:395420
TI Preparation of N-[(piperidinyl)benzyl]benzamides as chemokine receptor antagonists
IN Habashita, Hiromu; Nishizaki, Minoru; Hayashi, Kazuya; Shibayama, Shiro
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004092136	A1	20041028	2004WO-JP005504	20040416
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP-----1616862	A1	20060118	2004EP-000728041	20040416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US-20070043079	A1	20070222	2005US-000553704	20051018
PRAI	2003JP-000114172	A	20030418		
	2003JP-000346384	A	20031030		
	2004WO-JP005504	W	20040416		

OS MARPAT 141:395420
GI



I



II

AB The title compds. I [wherein R1 = (un)substituted aliphatic hydrocarbyl; ring A = (un)substituted heterocycle; ring B = (un)substituted cyclyl; G = a bond or a spacer; J = a spacer; K = a bond or a spacer; ring D = (un)substituted cyclyl], or salts, N-oxides, solvates, or prodrugs thereof are prepd as chemokine receptor (CCR) antagonists. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl inhibited human CCR5 with IC50 of 4.16 μM. I are useful for the treatment of various inflammations, autoimmune disorders, immunol. diseases, inflammation-associated infections, and HIV infection (no data). Formulations containing I as an active ingredient were also described.

IT 783345-29-9P 783345-30-2P 783345-31-3P
783345-32-4P 783345-33-5P 783345-34-6P
783345-35-7P 783345-36-8P 783345-37-9P
783345-38-0P 783345-39-1P 783345-40-4P
783345-41-5P 783345-42-6P 783345-43-7P
783345-44-8P 783345-45-9P 783345-46-0P
783345-47-1P 783345-48-2P 783345-49-3P
783345-50-6P 783345-51-7P 783345-52-8P

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
783345-69-7P 783345-70-0P 783345-74-4P
783345-75-5P 783345-76-6P 783345-77-7P
783345-78-8P 783345-79-9P 783345-80-2P
783345-81-3P 783345-82-4P 783345-83-5P
783345-84-6P 783345-85-7P 783345-86-8P
783345-87-9P 783345-88-0P 783345-89-1P
783345-90-4P 783345-91-5P 783345-92-6P
783346-39-4P 783346-40-7P 783346-41-8P
783346-42-9P 783346-43-0P 783346-44-1P
783346-45-2P 783346-46-3P 783346-47-4P
783346-48-5P 783346-49-6P 783346-50-9P
783346-51-0P 783346-52-1P 783346-53-2P
783346-54-3P 783346-55-4P 783346-56-5P
783346-57-6P 783346-58-7P 783346-59-8P
783346-60-1P 783346-61-2P 783346-62-3P
783346-63-4P 783346-64-5P 783346-65-6P
783346-66-7P 783346-68-9P 783346-69-0P
783346-70-3P 783346-71-4P 783346-72-5P
783346-73-6P 783346-74-7P 783346-75-8P
783347-15-9P 783347-16-0P 783347-44-4P
783347-47-7P 783347-48-8P 783347-49-9P
783347-50-2P 783347-51-3P 783347-53-5P
783347-54-6P 783347-55-7P 783347-56-8P
783347-57-9P 783347-58-0P 783347-59-1P
783347-63-7P 783347-65-9P 783347-66-0P
783347-67-1P 783347-68-2P 783347-73-9P
783347-74-0P 783347-75-1P 783347-76-2P
783347-77-3P 783347-78-4P 783347-79-5P
783347-80-8P 783347-81-9P 783347-82-0P
783347-83-1P 783347-84-2P 783347-85-3P
783347-86-4P 783347-89-7P 783347-90-0P
783347-91-1P 783347-92-2P 783347-93-3P
783347-94-4P 783347-95-5P 783347-96-6P
783347-98-8P 783347-99-9P 783348-00-5P
783348-16-3P 783348-18-5P 783348-19-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)

IT 783345-29-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)

RN 783345-29-9 HCAPLUS
CN Benzamide, N-[[3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]-4-(methylthio)- (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l39 tot

L39 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:902353 HCAPLUS
DN 141:395420
TI Preparation of N-[(piperidinyl)benzyl]benzamides as chemokine receptor antagonists
IN Habashita, Hiromu; Nishizaki, Minoru; Hayashi, Kazuya; Shibayama, Shiro
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004092136	A1	20041028	2004WO-JP005504	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1616862	A1	20060118	2004EP-000728041	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US-20070043079	A1	20070222	2005US-000553704	20051018
PRAI 2003JP-000114172	A	20030418		
2003JP-000346384	A	20031030		
2004WO-JP005504	W	20040416		

OS MARPAT 141:395420
GI



I



II

AB The title compds. I [wherein R1 = (un)substituted aliphatic hydrocarbyl; ring A = (un)substituted heterocycle; ring B = (un)substituted cyclyl; G = a bond or a spacer; J = a spacer; K = a bond or a spacer; ring D = (un)substituted cyclyl], or salts, N-oxides, solvates, or prodrugs thereof are prepd as chemokine receptor (CCR) antagonists. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl inhibited human CCR5 with IC50 of 4.16 μM. I are useful for the treatment of various inflammations, autoimmune disorders, immunol. diseases, inflammation-associated infections, and HIV infection (no data). Formulations containing I as an active ingredient were also described.

IT 783345-41-5P 783345-51-7P 783347-53-5P
783347-54-6P 783348-16-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-[(piperidinyl)benzyl]benzamide derivs. as

L39 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



• HCl

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
chemokine receptor antagonists)
RN 783345-41-5 HCAPLUS
CN Benzamide, N-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]phenyl]methyl]-2,4-dimethoxy- (CA INDEX NAME)



RN 783345-51-7 HCAPLUS
CN Benzamide, N-[[3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]phenyl]methyl]-2,4-dimethoxy- (CA INDEX NAME)



RN 783347-53-5 HCAPLUS
CN Benzamide, 2-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 783347-54-6 HCAPLUS
CN Benzamide, 3-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 783348-16-3 HCAPLUS
CN Benzamide, 4-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

=> d bib abs hitstr l25 tot

L25 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:611839 HCAPLUS
DN 143:133280
TI Preparation of 4-arylpiperidines as selective antagonists for melanin concentrating hormone-1 (MCH1) receptors.
IN Marzabadi, Mohammad R.; Wetzel, John M.; Chen, Chien-An; Deleon, John E.; Jiang, Yu; Lu, Kai
PA H. Lundbeck A/S, USA
SO U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20050154022	A1	20050714	2005US-000034611	20050113 <--
PRAI 2004US-00536585P	P	20040114 <--		

OS CASREACT 143:133280; MARPAT 143:133280
GI



AB Title compds. [I; X = CR1, N; if 1 X = N, the remaining X = CR1; R1 = H, F, Cl, Br, iodo, cyano, NO2, alkyl, alkoxy, fluoroalkyl, cycloalkylalkyl; R2 = H, F, Cl, Br, iodo, cyano, NO2, alkyl, alkoxy, fluoroalkyl; n = 2-6; B = CH2, CH(OH), O, CO; Y = C, N; Z = O, S, SO, SO2, CH2, CO, CH(OH), null; A = (substituted) Ph, heteroaryl], were prepared Thus, 5-(4-biphenylyl)valeric acid (preparation given), EDC, and DMAP were stirred together for 15 min. in CH2Cl2/DMF; tert-Bu 4-(5-amino-2-fluorophenyl)-1-piperidinecarboxylate (preparation given) was added followed by stirring for 24 h to give protected amide coupling product, which was stirred 2 h with 4N HCl in dioxane to give 15% N-[4-fluoro-3-(4-piperidinyl)phenyl]-5-(4-phenylphenyl)pentanamide. I showed MCH1 binding with Ki = 0.1-1000 nM.
IT 859170-25-5P 859170-27-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpiperidines as selective antagonists for melanin concentrating hormone-1 receptors)
RN 859170-25-5 HCAPLUS
CN Benzenebutanamide, N-[4-methyl-3-(4-piperidinyl)phenyl]-4-(2-pyridinyl)- (CA INDEX NAME)



RN 859170-27-7 HCAPLUS
CN Benzenepentanamide, N-[4-methyl-3-(4-piperidinyl)phenyl]-4-(4-pyridinyl)- (CA INDEX NAME)

L25 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L25 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:369221 HCAPLUS
DN 142:430024
TI Preparation of substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs as activators of caspases and inducers of apoptosis
IN Cai, Sui Xiong; Pervin, Azra; Kasibhatla, Shailaja; Nguyen, Bao Ngoc
PA Cytovia, Inc., USA
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005037196	A2	20050428	2004WO-US0032570	20041005 <--
WO--2005037196	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US-20070043076	A1	20070222	2006US-000572910	20060321 <--
PRAI 2003US-00508290P	P	20031006 <--		
2004WO-US0032570	W	20041005		

OS MARPAT 142:430024
GI





II

AB Substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs I [wherein Ar1, Ar2, Ar3 = independently (un)substituted hetero/aryl, hetero/arylalkyl, (partially) saturated carbocyclic, heterocyclic] were prepared as activators of caspases and inducers of apoptosis for treating neoplasm. For example, II was prepared by acylation of with 3-aminobenzotrifluoride malonyl dichloride and reaction of the diamide with 4-isopropylbenzaldehyde. II exhibited caspase activation (EC50 = 15 nM for human breast cancer cell line T-47D), inhibition of cell proliferation (GI50 = 180 nM for T-47D). II induced apoptosis in Jurkat and T-47D cells. I can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.
IT 850798-12-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 2-arylmethylene-N,N'-diarylmalonamides and analogs as activators of caspases and inducers of apoptosis)
RN 850798-12-8 HCAPLUS
CN Propanediamide, 2-[[4-(4-methyl-1-piperidinyl)phenyl]methylene]-N1,N3-bis[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L25 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:675728 HCAPLUS
DN 141:207205
TI Preparation of acrylamide derivatives as CCR antagonists
IN Shiraishi, Mitsuru; Seto, Masaki; Aikawa, Katsuji; Kanzaki, Naoyuki; Baba, Masanori
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 284 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004069808	A1	20040819	2004WO-JP0001181	20040205 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP--2004256530	A	20040916	2004JP-000029681	20040205 <--
EP-----1593673	A1	20051109	2004EP-000708471	20040205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US-20060160864	A1	20060720	2005US-0005442275	20050901 <--
PRAI 2003JP-000031068	A	20030207	<--	
2004WO-JP0001181	W	20040205	<--	

OS MARPAT 141:207205
GI



I

AB The title compds. I [R1 represents a 5- or 6-membered ring; R3 represents hydrogen, lower alkyl, or lower alkoxy; R7 and R8 each represents hydrogen or lower alkyl; Z1 represents a 5- or 6-membered aromatic ring; Z2 represents a group represented by Z2a-W1-Z2b- (Z2a and Z2b each represents oxygen, S(O)m (m is 0, 1, or 2), imino, or a bond and W1 represents an alkylene chain); X represents CR (R represents hydrogen, lower alkyl, lower alkoxy, or acyl, provided that R may form a 5- or 6-membered alicyclic heterocyclic group in cooperation with the adjacent R4) or nitrogen; R4 represents NR5R6 (R5 and R6 each represents hydrogen, a hydrocarbon group, a heterocyclic group, or acyl, or R5 is bonded to R6 to form a heterocyclic group represented by NR5R6); and R2 represents (1) amino in which the nitrogen atom may be in the form of a quaternary ammonium or oxide, (2) a nitrogenous heterocyclic group in which the ring-constituting atoms may include a sulfur or oxygen atom and the nitrogen atom may be in the form of a quaternary ammonium or oxide, etc.] are prepared For example, (S)-(2E)-3-[4-Azepan-1-yl-4'-(2-butoxyethoxy)-1,1'-biphenyl-3-yl]-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]acrylamide was prepared from (2E)-3-[4-azepan-1-yl-4'-(2-butoxyethoxy)-1,1'-biphenyl-3-yl]acrylic acid and (S)-4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]aniline. I have excellent antagonistic activity against CCR5 and are useful as preventive/therapeutic agents for diseases caused by HIV infection in human peripheral blood mononuclear cells, especially for AIDS. In an in vitro assay for CCR5 antagonism, compds. of this invention at 1 μM gave 89% to 100% CCR5 binding inhibition. Formulations are given.

IT 742098-55-1P 742098-56-2P 742098-59-5P
742098-60-8P 742098-66-4P 742098-67-5P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

L25 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
PREP (Preparation); USES (Uses)
(prepn. of acrylamide derivs. as CCR antagonists)

RN 742098-55-1 HCAPLUS
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 742098-56-2 HCAPLUS
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(1-piperidinyl)[1,1'-biphenyl]-3-yl]-2-methyl-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 742098-59-5 HCAPLUS
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(4-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L25 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 742098-60-8 HCAPLUS
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(4-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-2-methyl-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 742098-66-4 HCAPLUS
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(3-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L25 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 742098-67-5 HCAPLUS
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(2-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L25 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:892800 HCAPLUS
DN 139:395950
TI Preparation of substituted pyrazines as protein kinase modulators
IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PA Exelixis, Inc., USA
SO PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2003093297	A2	20031113	2003WO-US013869	20030502 <--
WO--2003093297	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2484209	A1	20031113	2003CA-002484209	20030502 <--
AU--2003234464	A1	20031117	2003AU-002234464	20030502 <--
EP-----1501514	A2	20050202	2003EP-000728690	20030502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP--2005530760	T	20051013	2004JP-000501436	20030502 <--
US-20060211709	A1	20060921	2005US-000513081	20050727 <--
PRAI 2002US-00377933P	P	20020503	<--	
2003WO-US013869	W	20030502	<--	

OS MARPAT 139:395950
GI



I

AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1

L25 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states assocd. with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.
IT 625463-00-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of protein kinase modulators)
RN 625463-00-5 HCAPLUS
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-(1-piperidinyl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:731704 HCAPLUS
DN 140:375048
TI Synthesis of plasmepsin II inhibitors - potential antimalarial agents
AU Mueller, Reto; Huerzeler, Marianne; Boss, Christoph
CS University of Applied Sciences Basel, Muttenz, CH-4132, Switz.
SO Molecules (2003), 8(7), 556-564
CODEN: MOLEFW; ISSN: 1420-3049
URL: http://www.mdpi.org/molecules/papers/80700556.pdf
PB Molecular Diversity Preservation International
DT Journal; (online computer file)
LA English
OS CASREACT 140:375048
AB A new series of plasmepsin II (PM II) inhibitors has been prepared based on 4-amino-1-tert.-butoxycarbonylpiperidine. These compds. might be useful as antimalarial drugs acting via a new mechanism, and therefore be less susceptible to parasite resistance now often observed with current antimalarial therapies. Some of the final compds. prepared exhibited encouraging inhibitory activity towards PM II.
IT 587878-57-7 587878-59-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of 4-[(N-cycloalkanoyl-N-benzyl)amino]piperidines as plasmepsin II inhibitors)
RN 587878-57-7 HCAPLUS
CN Cyclohexanecarboxamide, N-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 587878-59-9 HCAPLUS
CN Cyclohexanecarboxamide, N-[1-[(3-hydroxyphenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(4-pyridinyl)phenyl]methyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 587878-56-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 4-[(N-cycloalkanoyl-N-benzyl)amino]piperidines as plasmepsin II inhibitors)
RN 587878-56-6 HCAPLUS
CN Cyclohexanecarboxamide, N-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(4-pyridinyl)phenyl]methyl]-, trans- (CA INDEX NAME)

L25 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:324010 HCAPLUS
DN 139:100670
TI A Novel and Rapid Encoding Method Based on Mass Spectrometry for "One-Bead-One-Compound" Small Molecule Combinatorial Libraries
AU Song, Aimin; Zhang, Jinhua; Lebrilla, Carlito B.; Lam, Kit S.
CS Division of Hematology and Oncology Department of Internal Medicine, UC Davis Cancer Center, Sacramento, CA, 95817, USA
SO Journal of the American Chemical Society (2003), 125(20), 6180-6188
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 139:100670
AB A method for the preparation and encoding of readily deconvoluted combinatorial libraries is discussed. Beads are prepared with topol. segregated regions - an inner region to which is bound coding tags and an outer segment to which the library compound is bound. Coding blocks are attached to the inner resin by a cleavable methionine-containing linker; the coding blocks are chosen to have similar reactivities to the building blocks incorporated in the synthesis of the combinatorial library. Synthesis of the library leads to the functionalization of the library-containing portion of the resin bead and the coding portion of the resin bead. Cleavage of the linkers for the coding blocks from the resin bead by Edman degradation with cyanogen bromide yields lactones whose mass is determined by FT-MALDI mass spectroscopy. Anal. of the lactones isolated from a given bead yields the mass of each of the fragments present; by careful choice of coding blocks and reactants, the identities of the building blocks incorporated into a library bead and of the library member attached to that bead can be readily derived from the fragment masses. A combinatorial library is prepared and tested for the binding of library members to streptavidin; seventeen of the compds. are found to bind strongly to streptavidin by a colorometric assay and identified unambiguously by the library encoding method described here.
IT 560130-60-1P, Benzenepropanamide, β-(benzoylamino)-2-[(cyclohexylacetyl)amino]-5-(1-piperidinyl)-
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(preparation of combinatorial libraries on solid phase using beads with spatially segregated and functionalized linkers for the identification of library members by FT-MALDI mass spectrometry of fragments incorporated during synthesis)
RN 560130-60-1 HCAPLUS
CN Benzenepropanamide, β-(benzoylamino)-2-[(cyclohexylacetyl)amino]-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:754196 HCAPLUS
DN 137:257677
TI Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes
IN Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara
PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SO PCT Int. Appl., 449 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002076440	A2	20021003	2002WO-US0009100	20020321 <--
WO--2002076440	A3	20021128		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2002306848	A1	20021008	2002AU-000306848	20020321 <--
US-20060079533	A1	20060413	2004US-000472868	20040202 <--
PRAI 2001US-00278371P	P	20010323	<--	
2001US-00308729P	P	20010730	<--	
2002WO-US0009100	W	20020321	<--	

OS MARPAT 137:257677
GI



AB Disclosed are methods for treating or preventing Alzheimer's disease, and other diseases, and/or inhibiting β-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, using 3,4-disubstituted piperidinyl compds. (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined below. Although neither the compds. nor the methods of preparation are claimed, .apprx.150 example prepns., translations from the German examples of patent WO 9709311, are included. I inhibit β-secretase with IC50 < 50 μM; compds. that are effective inhibitors of β-secretase activity demonstrate reduced cleavage of the substrate as compared to a control. In I, R1 is aryl, heterocycle; R2 is Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, or furyl, optionally substituted. R3 is: H, hydroxy, lower-alkoxy, or lower-alkenyloxy; R4 is: H, lower-alkyl, lower-alkenyl, lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, benzyl, oxo, or where R3 and R4 together are a bond, or as specified in the claims. Q is: ethylene, or is absent; X is: a bond, -O-, -S-, -CH-R11- (R11 defined in claims), -CHOR9- (R9 defined in claims), -OCO, -CO-, or C:NOR10- (R10 is carboxyalkyl, alkoxycarbonylalkyl, alkyl or H), with the bond emanating from an O or S atom joining to a saturated C atom of group Z or to R1; W is: -O-, or -S-; Z is: lower-alkylene, lower-alkenylene, hydroxy-lower-alkylidene, -O-, -S-, -O-Alk- (Alk is a lower alkylene), -S-Alk-, -Alk-O-, or -Alk-S. N is: 1, or 0 or 1 when X is -O-CO; and where m is 0 or 1; with provisos.
IT 188863-69-6P, Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel-
188863-71-0P, Benzamide, N-[[4-[3-[(4-hydroxy-2-

L25 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, trans-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes)
RN 188863-69-6 HCAPLUS
CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-71-0 HCAPLUS
CN Benzamide, N-[[4-[(3R,4R)-3-[(4-hydroxy-2-naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 188863-75-4P, 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, trans- 188863-77-6P, 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[[2-(trimethylsilyl)ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, trans-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes)
RN 188863-75-4 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188863-77-6 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[[2-(trimethylsilyl)ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:675993 HCAPLUS
DN 137:216874
TI Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses
IN Ujjainwalla, Feroze; Chu, Lin; Goulet, Mark T.; Lee, Bonnie; Warner, Daniel; Wyvratt, Matthew J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002068388	A2	20020906	2002WO-US0005724	20020225 <--
WO--2002068388	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2439152	A1	20020906	2002CA-002439152	20020225 <--
AU--2002258414	A1	20020912	2002AU-002258414	20020225 <--
AU--2002258414	B2	20051215		
EE---200300415	A	20031215	2003EE-000000415	20020225 <--
EP-----1383501	A2	20040128	2002EP-000728357	20020225 <--
EP-----1383501	B1	20070404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU--2003003376	A2	20040128	2003HU-000003376	20020225 <--
HU--2003003376	A3	20070828		
JP--2004529105	T	20040924	2002JP-000567902	20020225 <--
NZ------527364	A	20041224	2002NZ-000527364	20020225 <--
CN-----1633297	A	20050629	2002CN-000805674	20020225 <--
BR--2002007658	A	20051025	2002BR-000007658	20020225 <--
AT------358481	T	20070415	2002AT-000728357	20020225 <--
ES------2283550	T3	20071101	2002ES-000728357	20020225 <--
US-20030225060	A1	20031204	2003US-000356879	20030203 <--
US-----6818658	B2	20041116		
ZA---2003006160	A	20040721	2003ZA-000006160	20030808 <--
BG------108132	A	20041230	2003BG-000108132	20030825 <--
IN-2003CN01342	A	20051125	2003IN-CN0001342	20030826 <--
NO---2003003812	A	20031028	2003NO-000003812	20030827 <--
MX--2003PA07785	A	20031208	2003MX-PA000778S	20030827 <--
US-20040266821	A1	20041230	2004US-000894719	20040720 <--
IN-2007CN02320	A	20071012	2007IN-CN0002320	20070529 <--
PRAI 2001US-0027258P	P	20010228	<--	
2001US-0030118P	P	20010622	<--	
2002WO-US0005724	W	20020225	<--	
2003US-000356897	A3	20030203	<--	
2003IN-CN0001342	A3	20030826	<--	

OS MARPAT 137:216874
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Certain novel 4-substituted N-acylated piperidine derivs., specifically I, are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R) [wherein: p = 1 or 2; q = 0, 1, or 2; n = 0, 1, or 2; R1 = H, amidino, alkyliminoyl, (un)substituted alkyl, (CH2)n-G1 [G1 = (un)substituted cycloalkyl, Ph,

L25 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
naphthyl, or heteroaryl]; R2 = (un)substituted Ph, naphthyl, or heteroaryl; X = alkyl, (CH2)n-G2 [G2 = (un)substituted cycloalkyl, Ph, naphthyl, heteroaryl, heterocyclyl, cyano, CONH2, CO2H, OH, NH2, and various derivs.] where any of (CH2)n may also be substituted; including pharmaceutically acceptable salts]. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Approx. 180 invention compds. I and approx. 25 intermediates were prepd. For instance, (2-bromo-5-chlorophenyl)acetic acid underwent a sequence of Me esterification, coupling with tert-Bu 4-[[(trifluoromethyl)sulfonyl]oxy]-3,6-dihydropyridine-1(2H)-carboxylate via a boronate ester, removal of the BOC group, and amidation with (3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid. The unsatd. amide-ester underwent hydrogenation, sapon. of the ester, and amidation with MeNH2.HCl, to give title compd. II. Representative compds. I bound to cloned human MC-4R in vitro with IC50 values generally below 2 μM, and also acted as agonists toward cloned human MCR in a functional assay with EC50 values less than 1 μM.
IT 455956-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylated piperidine derivs., particularly (pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists)
RN 455956-66-8 HCAPLUS
CN Benzeneacetamide, 5-chloro-N-cyclohexyl-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:438601 HCAPLUS
DN 138:100332
TI 4,4-Disubstituted cyclohexylamine NK1 receptor antagonists I
AU Elliott, Jason M.; Castro, Jose L.; Chicchi, Gary G.; Cooper, Laura C.; Dinnell, Kevin; Hollingworth, Gregory J.; Ridgill, Mark P.; Rycroft, Wayne; Kurtz, Marc M.; Shaw, Duncan E.; Swain, Christopher J.; Tsao, Kwei-Lan; Yang, Lihu
CS The Neuroscience Research Centre, Department of Medicinal Chemistry, Merck, Sharp & Dohme Research Laboratories, Harlow, Essex, CM20 2QR, UK
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(13), 1755-1758
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:100332
AB A series of novel 4,4-disubstituted cyclohexylamine based NK1 antagonists is described. The effect of changes to the C1-C4 relative stereochem. on the cyclohexane ring and replacements for the flexible linker are discussed, leading to the identification of compds. with high affinity and good in vivo duration of action.
IT 374821-73-5 488098-34-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and structure-activity relationship of 4,4-disubstituted cyclohexylamine NK1 receptor antagonists)
RN 374821-73-5 HCAPLUS
CN Benzamide, N-[[trans-4-[4-(4-fluorophenyl)-1-piperidinyl]-1-phenylcyclohexyl]methyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 488098-34-6 HCAPLUS
CN Benzamide, N-[[cis-4-[4-(4-fluorophenyl)-1-piperidinyl]-1-phenylcyclohexyl]methyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.



IT 488098-42-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and structure-activity relationship of 4,4-disubstituted cyclohexylamine NK1 receptor antagonists)
RN 488098-42-6 HCAPLUS
CN Benzamide, N-[[4-[4-(4-fluorophenyl)-1-piperidinyl]-1-

L25 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
phenylcyclohexyl]methyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:275961 HCAPLUS
DN 136:310177
TI Preparation of novel phenylalanine derivatives as inhibitors of integrin α4
IN Suzuki, Nobuyasu; Yoshimura, Toshihiko; Izawa, Hiroyuki; Sagi, Kazuyuki; Makino, Shingo; Nakanishi, Eiji; Murata, Masahiro; Tsuji, Takashi
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002028830	A1	20020411	2001WO-JP0008489	20010928 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2001090303	A	20020415	2001AU-000090303	20010928 <--
EP-----1323711	A1	20030702	2001EP-000970268	20010928 <--
EP-----1323711	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT------345127	T	20061215	2001AT-000970268	20010928 <--
US-20030220318	A1	20031127	2003US-000402006	20030331 <--
PRAI 2000JP-000299490	A	20000929	<--	
2001JP-000041885	A	20010219	<--	
2001WO-JP0008489	W	20010928	<--	

OS MARPAT 136:310177
GI



Q= Q1= Q2=



AB Specific phenylalanine derivs. (I) or pharmaceutically acceptable salts thereof [A = Q, Q1, Q2; X = CO, CR3R4; Y = bond, CR5R6, CR7:CR8, lower alkyl chain optionally containing 1 or 2 of O, S, or aromatic ring in the chain; Z = CR9R10, CR11R12CR13R14, lower alkyl or C2-3 alkylene chain optionally containing 1 or 2 of O, S, or aromatic ring in the chain; R1 - R14, R1', R2' = H, lower alkyl, alkenyl, alkynyl, or cycloalkyl optionally containing a hetero atom in the ring, aryl, heteroaryl, cycloalkyl (optionally containing a hetero

L25 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 409126-85-8 HCAPLUS
CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
atom)-lower alkyl or -lower alkoxy, aryl-lower alkyl, heteroaryl-lower alkyl, lower alkoxy, lower alkoxycarbonyl, lower alkylcarbonyl, cyano, NO2, lower alkylsulfonyl, lower alkylsulfonylamino, etc.; B = HO, lower alkoxy, hydroxyamino; E = H, lower alkyl, alkenyl, or alkynyl, cycloalkyl (optionally contg. a hetero atom in the ring)-lower alkyl, aryl-lower alkyl, heteroaryl-lower alkyl; D = lower alkyl, alkenyl, or alkynyl, lower alkoxy, hydroxyamino; E = H, lower alkyl, alkenyl, or alkynyl, cycloalkyl (optionally contg. a hetero atom in the ring)-lower alkyl or -lower alkoxy, aryl-lower alkyl, heteroaryl-lower alkyl, lower alkoxy, aryl-lower alkoxy, heteroaryl-lower alkoxy, etc.; T = bond, COP, SO, SO2, NHCO, NHCS, CH2CO, CH:CHCO; J, J' = H, halo, lower alkyl, lower alkoxy, NO2] are prepd. These compds. have an effect of inhibiting α4 integrin and, therefore, are useful as remedies or preventives for inflammatory diseases wherein the α4 integrin-dependent adhesion process participates in the pathol. conditions, for example, rheumatoid arthritis, inflammatory intestinal diseases, systemic lupus erythematosus, multiple sclerosis, Sjogren's disease, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arteriosclerosis, restenosis, tumor proliferation, tumor metastasis, and rejection in transplantation. Thus, a mixt. of 2,6-dichloro-4-(5-tetrazolyl)benzoic acid 35, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 30, 1-hydroxybenzotriazole monohydrate 23, Et3N 15, and (2S)-2-amino-3-[4-(4-methyl-1,3-dioxo-1,3-dihydroisoindol-2-yl)phenyl]propionic acid Et ester hydrochloride 35 mg in 5 mL CH2Cl2 was stirred at room temp. for 3 days, followed by treatment with a mixt. of 4 N HCl/dioxane and H2O to (2S)-2-((2,6-dichloro-4-(5-tetrazolyl)benzoyl)amino)-3-[4-(4-methyl-1,3-dioxo-1,3-dihydroisoindol-2-yl)phenyl]propionic acid (II). II in vitro inhibited the binding of VCAM-1 to human T-cell Jurkat expressing integrin α4β1 and that of VCAM-1 to human lymphoma B cell expressing integrin α4β7 with IC50 of 0.0059 and 0.00055 μM, resp.
IT 409126-83-6P 409126-84-7P 409126-85-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylalanine derivs. as inhibitors of integrin α4 and remedies or preventives for inflammatory diseases)
RN 409126-83-6 HCAPLUS
CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-(3,3-dimethyl-2,6-dioxo-1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 409126-84-7 HCAPLUS
CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-[(3R)-2,6-dioxo-3-phenyl-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:240729 HCAPLUS
DN 136:279344
TI Preparation of substituted amino-aza-cycloalkanes as anti-malarial agents
IN Boss, Christoph; Fischli, Walter; Meyer, Solange; Richard-Bildstein, Sylvia; Weller, Thomas
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002024649	A1	20020328	2001WO-EP0010272	20010906 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2423315	A1	20020328	2001CA-002423315	20010906 <--
AU--2001091830	A	20020402	2001AU-000091830	20010906 <--
EP-----1322612	A1	20030702	2001EP-000972013	20010906 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR--2001013989	A	20040127	2001BR-000013989	20010906 <--
HU--2003003360	A2	20040128	2003HU-000003360	20010906 <--
JP--2004509866	T	20040402	2002JP-000529062	20010906 <--
MX-2003PA01982	A	20040514	2003MX-PA0001982	20030306 <--
NO--2003001331	A	20030324	2003NO-000001331	20030324 <--
ZA--2003002290	A	20040630	2003ZA-000002290	20030324 <--
US-2004010431	A1	20040527	2003US-000381567	20030325 <--
PRAI 2000WO-EP0009328	W	20000925	<--	
2001WO-EP0010272	W	20010906	<--	

OS MARPAT 136:279344
GI





AB Title compds. I [Q = SO2R1, COR1, CONHR1, CONR1R2, COOR1, (CH2)pR1, (CH2)pCHR1R2; X = SO2R1, COR1, CONHR1, CONR1R2, COOR1, (CH2)pR1, (CH2)pCHR1R2, H; R1-3 = alk(en)yl, (hetero)aryl, cycloalkyl, heterocyclyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, heterocyclyl-alkyl, etc.; R4 = H, CH2OR5, COOR5; R5 = H, (cyclo)alkyl, (hetero)aryl, heterocyclyl, cycloalkyl-alkyl, aryl-alkyl, etc.; q = 0-1, in case t=0, R4 is absent; m = 2-4; n = 1-2; p =0-2] were prepared Examples include characterization and

L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
bioassay data for over 100 compds. For instance, 1-benzyl-4-[(4-(benzyloxy)benzyl]amino]piperidine was acylated with 4-pentylbenzoyl chloride to give II. II had IC50 = 70 nM for plasmepsin II. I are useful as inhibitors of the plasmodium falciparum protease plasmepsin II or related aspartic proteases.

IT 405513-81-7P 405513-87-3P 405513-89-5P
405513-96-4P 405514-03-6P 405514-06-9P
405514-08-1P 405514-09-2P 405514-12-7P
405514-14-9P 405514-15-0P 405514-20-7P
405514-21-8P 405514-26-3P 405514-27-4P
405514-64-9P 405514-65-0P 405514-66-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of substituted amino-aza-cycloalkanes as anti-malarial agents)

RN 405513-81-7 HCAPLUS
CN Benzamide, N-[1-(3-methylbutyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405513-87-3 HCAPLUS
CN Benzamide, 4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]-N-[1-(3-thienylmethyl)-4-piperidinyl]- (CA INDEX NAME)

PAGE 1-A



L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 405513-89-5 HCAPLUS
CN Benzamide, N-[1-(cyclohexylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405513-96-4 HCAPLUS
CN Benzamide, N-[1-(3-furanylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 405514-03-6 HCAPLUS
CN Benzamide, N-[1-(1-cyclohexen-1-ylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-

L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-06-9 HCAPLUS
CN Benzamide, 4-pentyl-N-[1-(4-pyridinylmethyl)-4-piperidinyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-08-1 HCAPLUS
CN Benzamide, 4-pentyl-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-09-2 HCAPLUS
CN Benzamide, N-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-12-7 HCAPLUS
CN Benzamide, N-[1-(1-cyclohexen-1-ylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 405514-14-9 HCAPLUS
CN Benzamide, N-[1-[[5-(hydroxymethyl)-2-furanyl]methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-15-0 HCAPLUS
CN Benzamide, N-[1-(cyclopropylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-20-7 HCAPLUS
CN Benzamide, N-[1-(3-furanylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 405514-21-8 HCAPLUS
CN Benzamide, 4-pentyl-N-[1-(4-pyridinylmethyl)-4-piperidinyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-26-3 HCAPLUS
CN Benzamide, 4-pentyl-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 405514-27-4 HCAPLUS
CN Benzamide, N-[1-(2-benzofuranylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-64-9 HCAPLUS
CN Benzamide, 4-pentyl-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-65-0 HCAPLUS
CN Benzamide, N-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-66-1 HCAPLUS
CN Benzamide, N-[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L25 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:51416 HCAPLUS
DN 136:102196
TI Biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein
IN Priepke, Henning; Hauel, Norbert; Thomas, Leo; Mark, Michael; Dahmann, Georg
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2002004403	A1	20020117	2001WO-EP0007627	20010704 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE----10033337	A1	20020117	2000DE-10033337	20000708 <--
	CA-----2412116	A1	20021209	2001CA-002412116	20010704 <--
	EP-----1301464	A1	20030416	2001EP-000945336	20010704 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR				
	JP--2004502749	T	20040129	2002JP-000509071	20010704 <--
	US-20020032238	A1	20020314	2001US-000899884	20010706 <--
	MX-2002PA12910	A	20040505	2002MX-PA0012910	20021219 <--
PRAI	2000DE-10033337	A	20000708	<--	
	2000US-002201158P	P	20000724	<--	
	2001WO-EP0007627	W	20010704	<--	

OS MARPAT 136:102196
GI



I



II

AB Biphenylcarboxamides I [R1, R2, R3 = H, F, Cl, Br, alkyl, fluoroalkyl, OH, alkoxy, (un)substituted NH2; R1R2 = 2,2'-CO; R4, R5 = H, alkyl; R6 = H, alkyl, (un)substituted NH2; NR5R6 = heterocyclic; R7 = H, F, Cl, Br, I, alkyl, alkoxy, NO2, amino] were prepared for use as inhibitors of the microsomal triglyceride transfer protein with IC50 ≤ 100μM. Thus, the amide II was prepared from 2-(4-MeC6H4)C6H4CONHC6H4COCl-3 and the

L25 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
pyrazolylbenzylamine. The latter compd. was obtained by reaction of 4-NCC6H4NHNH2 with PhCOCH2COMe and redn. of the cyano group. The acid chloride was obtained by treating 3-H2NC6H4CO2Et with 2-(4-MeC6H4)C6H4COCl, ester hydrolysis and conversion to the chloride.
IT 389601-48-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylcarboxylamides as inhibitors of microsomal triglyceride transfer protein)
RN 389601-48-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[[[4-(1-piperidinyl)phenyl]methyl]amino]carbonyl]phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:851143 HCAPLUS
DN 136:5742
TI Preparation of cyclohexane derivatives for therapeutic use in the treatment of disorders, such as depression, anxiety, pain, inflammation, migraine, and vomiting
IN Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2001087866	A1	20011122	2001WO-GB002136	20010516 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA-----2410077	A1	20011122	2001CA-002410077	20010516 <--
	EP-----1286978	A1	20030305	2001EP-000929825	20010516 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP--2003533519	T	20031111	2001JP-000584262	20010516 <--
	AU------781480	B2	20050526	2001AU-000056505	20010516 <--
	US--2003025059	A1	20031204	2002US-000276129	20021113 <--
	US-----6953792	B2	20051011		
PRAI	2000GB-000012214	A	20000519	<--	
	2001WO-GB0002136	W	20010516	<--	
OS	MARPAT 136:5742				
GI					



I



II

AB Cyclohexane derivs., such as I [R = substituted or unsubstituted Ph or pyridinyl; R1 = H, SH, NH2, alkyl, alkenyl, cycloalkyl, alkoxy, amino, alkylthio, etc.; R2 = H, halogen, alkyl, alkoxy; R3 = H, CN, SH, halogen, alkyl, alkoxy, amino, carboxy, acyl, etc.; R6 = H, OH, alkyl; R7 = H, OH, aminoalkyl, carboxyalkyl, carbocyclyl, C-linked heterocyclyl; X = linking group, such as -CONR13CR14R15-, -CR14R15NR13CO-; R13 = H, alkyl,

L25 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
alkylcarbonyl; R14, R15 = H, OH, CHO, alkyl, alkenyl, aminoalkyl, carboxyl; R14R15 = -(CH2)2-], were prepd. for pharmaceutical use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia, and treatment or prevention of physiol. disorders assocd. with an excess of tachykinins. Thus, cyclohexane deriv. II was prepd. via a multistep synthetic sequence which was concluded with the amination of the corresponding cyclohexanone with 4-(4-fluorophenyl)piperidine. Dosages of the prepd. cyclohexanes were discussed, however, biol. activity data was not presented.
IT 374821-73-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexane derivs. for therapeutic use in the treatment of disorders, such as depression, anxiety, pain, inflammation, migraine, and vomiting)
RN 374821-73-5 HCAPLUS
CN Benzamide, N-[[trans-4-[4-(4-fluorophenyl)-1-piperidinyl]-1-phenylcyclohexyl]methyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:833284 HCAPLUS
DN 135:371641
TI Preparation of arylheterocyclylamides as motilin antagonists
IN Johnson, Sigmond G.; Rivero, Ralph A.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2001085694	A2	20011115	2001WO-US0011821	20010411 <--
	WO--2001085694	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US-20020013352	A1	20020131	2001US-000829767	20010410 <--
	US-----6511980	B2	20030128		
	CA-----2408288	A1	20011115	2001CA-002408288	20010411 <--
	AU--2001053374	A	20011120	2001AU-000053374	20010411 <--
	EP-----1294695	A2	20030326	2001EP-000926866	20010411 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP--2003532710	T	20031105	2001JP-000582295	20010411 <--
	BG------107243	A	20030731	2002BG-000107243	20021101 <--
	MX-2002PA10896	A	20040906	2002MX-PA0010896	20021105 <--
	US-20030203906	A1	20031030	2002US-000291133	20021108 <--
	US-----6967199	B2	20051122		
	US-20050148584	A1	20050707	2005US-000066202	20050225 <--
	US-----7112586	B2	20060926		
	US-20060183741	A1	20060817	2006US-000386960	20060426 <--
	US-----7166601	B2	20070123		
	US-20070054888	A1	20070308	2006US-000555914	20061102 <--
PRAI	2000US-000202131P	P	20000505	<--	
	2001US-000829767	A3	20010410	<--	
	2001WO-US0011821	W	20010411	<--	
	2002US-000291133	A3	20021108	<--	
	2005US-000066202	A3	20050225		
	2006US-000386960	A3	20060426		
OS	MARPAT 135:371641				
GI					

L25 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. [I; R1 = H, (substituted) aryl, aralkyl, heterocyclyl, diarylalkyl, alkyl, etc.; R2 = (substituted) aryl, aralkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, etc.; X1-X4 = null, CO, SO2; R1NR2X1 = (substituted) heterocyclyl; A = (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, etc.; Y = O, NH, S, SO2; n = 0-5; R4 = H, amino, alkylamino, dialkylamino, heterocyclyl, alkylheterocyclyl, etc.], were prepared Thus, N-[3-[2-(1-pyrrolidino)ethoxy]phenyl]-N-(cis-3-aminocyclohexyl)methyl-4-fluorophenylcarboxamide (preparation given) and PhCHO in PhMe were treated sequentially with Ti(OiPr)4, EtOH, and NaBH(OAc)3 to give a crude residue which in CH2Cl2 was treated with Me3CCOCl to give title compound (II). II inhibited motilin-induced contraction in rabbit colon with IC50 = 0.029 μM.

IT 373805-43-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylheterocyclylamides as motilin antagonists)

RN 373805-43-7 HCAPLUS

CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 363627-25-2 HCAPLUS

CN Benzamide, 3,5-dimethoxy-4-(phenylmethoxy)-N-[[1-(1-piperidinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 363627-29-6 HCAPLUS

CN Benzamide, 4-phenoxy-N-[[1-(1-piperidinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 363627-30-9 HCAPLUS

CN Benzamide, 4-(phenylmethoxy)-N-[[1-(1-piperidinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 363627-39-8 HCAPLUS

CN Benzamide, 4-methoxy-3-(phenylmethoxy)-N-[[1-(1-piperidinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:534606 HCAPLUS

DN 135:266639

TI The first potent and selective inhibitors of the glycine transporter type 2

AU Caulfield, Wilson L.; Collie, Iain T.; Dickins, Rachel S.; Epemolu, Ola; McGuire, Ross; Hill, David R.; McVey, Gillian; Morphy, J. Richard; Rankovic, Zoran; Sundaram, Hardy

CS Lead Discovery Unit, Organon Laboratories Ltd., Newhouse, ML1 5SH, UK

SO Journal of Medicinal Chemistry (2001), 44(17), 2679-2682
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 135:266639

AB Glycine is one of the major inhibitory neurotransmitters in the spinal cord and brain stem of vertebrates. The inhibitory actions of glycine are mediated by the strychnine-sensitive glycine receptor, a ligand-gated chloride channel distributed throughout the spinal cord and brain stem. Glycine is also known to potentiate the action of glutamate acting as an essential co-agonist on postsynaptic N-methyl-d-aspartate (NMDA) receptors. Synaptic levels of glycine are believed to be controlled by high-affinity glycine transporters. These transporters are members of a large family of sodium/chloride-dependent transporters, which are composed of single oligomeric proteins containing 12 hydrophobic membrane-spanning domains. There is evidence that glycine-mediated inhibition produces muscle relaxation and blockade of this inhibition produces convulsions. Therefore, we postulated that modulators of endogenous levels of glycine might provide skeletal muscle relaxation. A significant amount of data has accumulated over recent years, indicating that glycine also has an important role in the modulation of nociceptive pathways. Thus, it was anticipated that an increase in synaptic levels of endogenous glycine by a selective inhibition of the GlyT-2 transporter in the spinal cord may offer a unique approach for developing a novel muscle relaxant, anesthetic, and/or analgesic reagent, suitable for use during surgical anesthesia. Due to the discrete localization of both ssGlyR and the GlyT-2 transporter within the spinal cord and brain stem, a glycine modulator might not be expected to lead to serious CNS side effects that are characteristic for currently used μ-opioid analgesics. Since testing of this hypothesis has been hampered by the lack of a suitable GlyT-2 inhibitor, we sought a potent and selective inhibitor of the transporter that would enable us to conduct proof-of-principle studies. In summary, high-throughput screening of Organon's compound collection provided an attractive drug-like GlyT-2 inhibitor suitable for high-throughput synthesis. A detailed study of the SAR and rapid hit optimization were achieved through synthesis of a solution-phase 2D library. This led to identification of 4-benzyloxy-3,5-dimethoxy-N-[(1-dimethylaminocyclopentyl)methyl]benzamide, the first potent and selective GlyT-2 inhibitor.

IT 363627-24-1P 363627-25-2P 363627-29-6P
363627-30-9P 363627-39-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(structure-activity relationship of selective glycine transporter type 2 inhibitors)

RN 363627-24-1 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[[1-(1-piperidinyl)cyclohexyl]methyl]- (CA INDEX NAME)



L25 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:690830 HCAPLUS

DN 131:299465

TI Preparation of N-acyl and N-aroyl aralkyl amides as 5-HT1 agonists or antagonists

IN Howard, Harry Ralph

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP------952154	A2	19991027	1999EP-000302284	19990325 <--
	EP------952154	A3	20000105		
	EP------952154	B1	20040818		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO				
	AT------273970	T	20040915	1999AT-000302284	19990325 <--
	PT------952154	T	20041231	1999PT-000302284	19990325 <--
	ES------2226284	T3	20050316	1999ES-000302284	19990325 <--
	CA------2269049	A1	19991016	1999CA-002269049	19990414 <--
	US------6323229	B1	20011127	1999US-000291454	19990414 <--
	JP-2000026385	A	20000125	1999JP-000108227	19990415 <--
	JP------3308225	B2	20020729		
	BR------9901058	A	20000509	1999BR-000001058	19990416 <--
	US------6197773	B1	20010306	2000US-000584680	20000531 <--
	US------6451803	B1	20020917	2000US-000583691	20000531 <--
PRAI	1998US-00081970P	P	19980416	<--	
	1999US-000291454	A3	19990414	<--	

OS MARPAT 131:299465

GI



I II III



IV

AB The title compds. [I; R1 = II, III, etc.; a = 0-8; m = 0-4; X = H, Cl, F, Br, etc.; R2 = (CH2)tB; t = 0-3; B = H, Ph, naphthyl, etc.; R3, R4 = H, alkyl, etc.; R5 = H, alkyl; R6 = H, alkyl, etc.; R8 = H, alkyl; R13 = alkyl, Cl-4 alkylene bridge from one of the ring carbons of the piperazine or piperidine ring to the same or another ring carbon or a ring nitrogen of the piperazine or piperidine ring, etc.], useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated, were prepared E.g., a 3- and 4-step syntheses of the title compound IV, starting with 2-(4-methylpiperazin-1-yl)benzaldehyde, were given. All compds. I that were tested exhibited IC50 of < 0.60 μM for 5-HT1D affinity and IC50 of < 1.0 μM for 5-HT1A affinity.

IT 247157-70-6P 247157-80-8P

L25 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-acyl and N-aroyl aralkyl amides as 5-HT1 agonists or antagonists)
RN 247157-70-6 HCAPLUS
CN Benzamide, 3,4-dichloro-N-[2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]-(CA INDEX NAME)



RN 247157-80-8 HCAPLUS
CN Benzamide, N-[2-[2-(1,4-dimethyl-4-piperidinyl)phenyl]ethyl]-4-fluoro-(CA INDEX NAME)



L25 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:348249 HCAPLUS
DN 131:102177
TI Substituted piperidines - highly potent renin inhibitors due to induced fit adaptation of the active site
AU Vieira, Eric; Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; Guller, Rolf; Hirth, Georges; Marki, Hans Peter; Muller, Marcel; Oefner, Christian; Scalone, Michelangelo; Stadler, Heinz; Wilhelm, Maurice; Wostl, Wolfgang
CS Pharma Research Departments, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switz.
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(10), 1397-1402
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I

AB The identification, synthesis and activity of a novel class of piperidine renin inhibitors, e.g., I, is presented. The most active compds. show activities in the picomolar range and are among the most potent renin inhibitors ever identified.
IT 188863-69-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(piperidine renin inhibitors)
RN 188863-69-6 HCAPLUS
CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:191411 HCAPLUS
DN 130:242312
TI Pharmaceutical preparations containing piperidine derivatives as antimalarials
IN Bur, Daniel; Fischli, Walter; Matile, Hugues; Ridley, Robert George; Wostl, Wolfgang
PA F.Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-----9912532	A2	19990318	1998WO-EP0005570	19980902 <--
WO-----9912532	A3	19990729		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU-----9897409	A	19990329	1998AU-000097409	19980902 <--
PRAI 1997EP-000115510	A	19970908	<--	
1998WO-EP0005570	W	19980902	<--	

AB Pharmaceutical prepns. containing piperidine derivs. are used against chloroquine-sensitive and chloroquine-resistant pathogens and in the production of corresponding medicaments; furthermore corresponding medicaments and a method of treating malaria in a patient in need of such treatment comprises administering to said patient an effective amount of a corresponding compound or medicament. The IC50 of (3R5,4R5)-3-(naphthalen-2-ylmethoxy)-4-(4-(2-phenoxy-ethoxy)-phenyl)-piperidine (I) against chloroquine-resistant strains of Plasmodium falciparum was 0.6 μM. A tablet contained I 500, lactose 149, PVP 15, dioctyl sodium sulfosuccinate 1, sodium carboxymethyl starch 30, and magnesium stearate 5 mg.
IT 188863-69-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical prepns. containing piperidine derivs. as antimalarials)
RN 188863-69-6 HCAPLUS
CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:307688 HCAPLUS
DN 126:277402
TI New 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes for treating heart and kidney insufficiency
IN Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; Gueller, Rolf; Hirth, Georges; Maerki, Hans-Peter; Mueller, Marcel; Oefner, Christian; Stadler, Heinz; Vieira, Eric; Wilhelm, Maurice; Wostl, Wolfgang
PA F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 492 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-----9709311	A1	19970313	1996WO-EP0003803	19960829 <--
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IN-1996MA01426	A	20050304	1996IN-MA0001426	19960813 <--
CA-----2230931	A1	19970313	1996CA-002230931	19960829 <--
AU-----9667432	A	19970327	1996AU-000067432	19960829 <--
AU-----708616	B2	19990805		
EP-----863875	A1	19980916	1996EP-000927715	19960829 <--
EP-----863875	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN-----1202152	A	19981216	1996CN-000197674	19960829 <--
JP----11500447	T	19990112	1997JP-000510837	19960829 <--
JP-----3648251	B2	20050518		
BR-----9610385	A	19990706	1996BR-000010385	19960829 <--
HU-----9900926	A2	19990928	1999HU-000000926	19960829 <--
HU-----9900926	A3	20021228		
NZ------315677	A	20000228	1996NZ-000315677	19960829 <--
RU-----2167865	C2	20010527	1998RU-000106388	19960829 <--
AT------242213	T	20030615	1996AT-000927715	19960829 <--
IL------123293	A	20030624	1996IL-000123293	19960829 <--
CZ------292327	B6	20030917	1998CZ-000000684	19960829 <--
PT------863875	T	20031031	1996PT-000927715	19960829 <--
ES-----2201192	T3	20040316	1996ES-000927715	19960829 <--
PL------193686	B1	20070330	1996PL-000325425	19960829 <--
ZA-----9607424	A	19970307	1996ZA-000007424	19960902 <--
TW------474932	B	20020201	1996TW-085110684	19960902 <--
NO-----9800954	A	19980428	1998NO-000000954	19980305 <--
NO-----310069	B1	20010514		
US-----6051712	A	20000418	1999US-000255185	19990222 <--
HK-----1016177	A1	20060901	1999HK-000101299	19990330 <--
US-----6150526	A	20001121	1999US-000456283	19991207 <--
PRAI 1995CH-000002548	A	19950907	<--	
1996CH-000001876	A	19960726	<--	
1996WO-EP0003803	W	19960829	<--	
1996US-000711339	A3	19960906	<--	
1999US-000255185	A1	19990222	<--	

OS MARPAT 126:277402
GI



I

AB New piperidine and azabicyclooctane derivs. (> 1000 compds.) are renin inhibitors for treatment of high blood pressure, heart and kidney

L25 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
insufficiency. Thus, the piperidine deriv. I was prepd. from 1-benzyl-3-propyl-4-piperidinone by reaction with 4-FC6H4Br, followed by 1-benzyloxy-3-chloromethylnaphthalene and deblocking. I had a renin-inhibiting IC50 of 0.317 μM.

IT 188863-75-4P 188863-77-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)

RN 188863-75-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-77-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[(2-(trimethylsilyl)ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 188863-69-6P 188863-71-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)

RN 188863-69-6 HCAPLUS

CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188863-71-0 HCAPLUS

CN Benzamide, N-[[4-[(3R,4R)-3-[(4-hydroxy-2-naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:55 HCAPLUS

DN 126:47237

TI Preparation of N-[(acylamidino)phenyl]oxazolidinones and analogs as adhesion receptor antagonists

IN Gante, Joachim; Juraszyk, Horst; Raddatz, Peter; Wurziger, Hanns; Bernotat-Danielowski, Sabine; Melzer, Guido

PA Merck Patent Gmbh, Germany

SO Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP------741133	A2	19961106	1996EP-000106423	19960424 <--
	EP------741133	A3	19970129		
	EP------741133	B1	20040128		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE-----19516483	A1	19961107	1995DE-100016483	19950505 <--
	TW------378205	B	20000101	1996TW-085103612	19960326 <--
	AT------258548	T	20040215	1996AT-000106423	19960424 <--
	PT------741133	T	20040630	1996PT-000106423	19960424 <--
	ES-----2213758	T3	20040901	1996ES-000106423	19960424 <--
	IN-1996CA00767	A	20050304	1996IN-CA00000767	19960426 <--
	RU-----2162086	C2	20010120	1996RU-000108122	19960429 <--
	AU-----9651969	A	19961114	1996AU-000051969	19960430 <--
	AU------708813	B2	19990812		
	PL------187000	B1	20040430	1996PL-000314044	19960430 <--
	JP-----08301857	A	19961119	1996JP-000134137	19960502 <--
	ZA-----9603535	A	19960808	1996ZA-000003535	19960503 <--
	CA-----2175767	A1	19961106	1996CA-002175767	19960503 <--
	NO-----9601813	A	19961106	1996NO-000001813	19960503 <--
	CN-----1138037	A	19961218	1996CN-000106225	19960503 <--
	CN-----1134422	B	20040114		
	BR-----9602150	A	19980630	1996BR-000002150	19960503 <--
	HU-----9601176	A2	19980728	1996HU-000001176	19960503 <--
	HU-----9601176	A3	19980828		
	US-----6455529	B1	20020924	1996US-000642268	19960503 <--
	CZ------291621	B6	20030416	1996CZ-000001295	19960503 <--
	SK------282563	B6	20021008	1996SK-000000573	19960506 <--
PRAI	1995DE-100016483	A	19950505	<--	

OS MARPAT 126:47237

GI



AB Title compds. [e.g., I; R = azino group Q; R1 = H, alkyl, arylcarbonyl, alkoxy, etc.; R3 = alkanoyl, (hetero)arylcarbonyl, alkoxycarbonyl, etc.; Z = CH2, CO, CS; z1 = CH2 and Z2 = CR10(CH2)mCOR2; Z1 = CH2, CO, or CS and Z2 = NCHR9(CH2)nCOR2; R2 = OH, alkoxy, NH2, etc.; R9 = H, CO2H, alkoxycarbonyl; R10 = H or OH; m = 0-4; n = 0-3] were prepared as adhesion receptor antagonists (no data). Thus, I (R1 = H, R3 = Bz, Z = CH2)(II; R = OSO2Me) (preparation described) was aminated by 1-(ethoxycarbonylmethyl)piperazine to give II (R = 4-(ethoxycarbonylmethyl)piperazino).

IT 184634-48-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[(acylamidino)phenyl]oxazolidinones and analogs as adhesion receptor antagonists)

RN 184634-48-8 HCAPLUS

CN [1,4'-Bipiperidine]-4-carboxylic acid, 1'-[4-[(benzoylamino)iminomethyl]phenyl]-, ethyl ester (CA INDEX NAME)

L25 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L25 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:867627 HCAPLUS
DN 123:256743
TI Preparation of amino-substituted benzenesulfonurea and -thiourea cardiovascular agents
IN Enlert, Heinrich; Mania, Dieter; Hartung, Jens; Goegelein, Heinz; Kaiser, Joachim
PA Hoechst A.-G., Germany
SO Ger. Offen., 15 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE-----4341655	A1	19950608	1993DE-004341655	19931207 <--
	TW-----383298	B	20000301	1994TW-083104566	19940520 <--
	EP-----657423	A1	19950614	1994EP-000118931	19941201 <--
	EP-----657423	B1	19981230		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT-----175192	T	19990115	1994AT-000118931	19941201 <--
	ES-----2127875	T3	19990501	1994ES-000118931	19941201 <--
	FI-----9405729	A	19950608	1994FI-000005729	19941205 <--
	FI-----107152	B1	20010615		
	AU-----9480213	A	19950615	1994AU-000080213	19941205 <--
	AU-----678866	B2	19970612		
	CN-----1111238	A	19951108	1994CN-000119386	19941205 <--
	CN-----1054372	B	20000712		
	HU-----71125	A2	19951128	1994HU-000003486	19941205 <--
	HU-----219228	B	20010328		
	US-----5476850	A	19951219	1994US-000353263	19941205 <--
	IL-----111870	A	19990312	1994IL-000111870	19941205 <--
	CA-----2137441	A1	19950608	1994CA-002137441	19941206 <--
	CA-----2137441	C	20051018		
	NO-----9404699	A	19950608	1994NO-000004699	19941206 <--
	ZA-----9409687	A	19950710	1994ZA-000009687	19941206 <--
	JP-----07196597	A	19950801	1994JP-000301739	19941206 <--
	JP-----3718246	B2	20051124		

PRAI 1993DE-004341655 A 19931207 <--
OS MARPAT 123:256743
GI



I



II

AB The title compds. (I; E = O, S; R1 = H, alkyl, fluoroalkyl; R2 = undefined; X = H, F, Cl, I, alkyl; Y = hydrocarbyl; Z = F, Cl, I, alkyl, NO2, alkoxy), useful as cardiovascular agents and antiarrhythmics, are prepared Thus, sulfonylthiourea II, m.p. 236°, prepared by the addition reaction of the corresponding sulfonamide with Me isothiocyanate, demonstrated cardiovascular activity.

L25 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 169195-72-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino-substituted benzenesulfonurea and -thiourea cardiovascular agents)
RN 169195-72-6 HCAPLUS
CN Benzamide, 5-chloro-2-methoxy-N-[2-[3-[[[(methylamino)thioxomethyl]amino]sulfonyl]-4-(1-piperidinyl)phenyl]ethyl]- (CA INDEX NAME)



IT 169195-76-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino-substituted benzenesulfonurea and -thiourea cardiovascular agents from)
RN 169195-76-0 HCAPLUS
CN Benzamide, N-[2-[3-(aminosulfonyl)-4-(1-piperidinyl)phenyl]ethyl]-5-chloro-2-methoxy- (CA INDEX NAME)



L25 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:593148 HCAPLUS
DN 83:193148
OREF 83:30373a,30376a
TI Preparation and reactions of [dialkylamino]aryl]methylene-substituted azlactones (oxazol-5-ones)
AU Niewiadomski, Krzysztof B.; Suschitzky, Hans
CS Ramage Lab., Univ. Salford, Salford, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1975), (17), 1679-82
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 83:193148
GI For diagram(s), see printed CA Issue.
AB O-(dialkylamino)benzaldehydes, prepared from o-FC6H4CHO and morpholine, pyrrolidine, piperidine, and dihydroazepine in hot THF, with BzNHCH2CO2H gave the azlactones I [X = O, (CH2)n, n = 0-2; R = H, resp.]. I with EtOH-NaOH, MeOH-NaOAc, N2H4, p-EtO2CC6H4NH2 gave the amides II (R = CO2H, CO2Me, CONHNH2, CONHC6H4CO2Et-p, resp.), and with PhMgBr gave carbinols II [R = CPh2OH, X = (CH2)n] which in HCl cyclized to indenes III (n = 0-2). The azlactones I (R = NO2) prepared from 2,4-Cl(O2N)C6H4CHO, reacted similarly.
IT 58029-16-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)
RN 58029-16-6 HCAPLUS
CN Benzamide, N-[1-(hydroxydiphenylmethyl)-2-[2-(1-piperidinyl)phenyl]ethenyl]- (CA INDEX NAME)



IT 58028-86-7P 58028-90-3P 58028-92-5P
58028-96-9P 58028-98-1P 58029-02-0P
58029-03-1P 58029-04-2P 58029-07-5P
58029-09-7P 58029-14-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 58028-86-7 HCAPLUS
CN 2-Propenoic acid, 2-(benzoylamino)-3-[5-nitro-2-(1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 58028-90-3 HCAPLUS
CN 2-Propenoic acid, 2-(benzoylamino)-3-[2-(1-piperidinyl)phenyl]- (CA INDEX NAME)



L25 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 58028-92-5 HCAPLUS
CN 2-Propenoic acid, 2-(benzoylamino)-3-[5-nitro-2-(1-piperidinyl)phenyl]-, methyl ester (CA INDEX NAME)



RN 58028-96-9 HCAPLUS
CN 2-Propenoic acid, 2-(benzoylamino)-3-[2-(1-piperidinyl)phenyl]-, methyl ester (CA INDEX NAME)



RN 58028-98-1 HCAPLUS
CN 2-Propenoic acid, 2-(benzoylamino)-3-[5-nitro-2-(1-piperidinyl)phenyl]-, hydrazide (CA INDEX NAME)



RN 58029-02-0 HCAPLUS
CN 2-Propenoic acid, 2-(benzoylamino)-3-[2-(1-piperidinyl)phenyl]-, 2-(4-nitrophenyl)hydrazide (CA INDEX NAME)



RN 58029-03-1 HCAPLUS
CN Benzoic acid, 4-[[2-(benzoylamino)-1-oxo-3-[2-(1-piperidinyl)phenyl]-2-propenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L25 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 58029-04-2 HCAPLUS
CN Benzamide, N-[2-[2-(1-piperidinyl)phenyl]-1-(1-pyrrolidinylcarbonyl]ethenyl]- (CA INDEX NAME)



RN 58029-07-5 HCAPLUS
CN Phenylalanine, N-benzoyl-2-(1-piperidinyl)-, methyl ester (CA INDEX NAME)



RN 58029-09-7 HCAPLUS
CN Phenylalanine, 5-amino-N-benzoyl-2-(1-piperidinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 58029-14-4 HCAPLUS
CN Phenylalanine, N-benzoyl-5-(benzoylamino)-2-(1-piperidinyl)- (CA INDEX NAME)

L25 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L25 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:461917 HCAPLUS
DN 77:61917
OREF 77:10247a,10250a
TI Aminobenzenes. VIII. Rearrangement of phenyl carbamates. Syntheses of 2,4-dioxo-3,4-dihydro-2H-1,3-benzoxazines and salicylamides
AU Effenberger, Franz; Niess, Rolf; Schick, Max
CS Inst. Org. Chem., Univ. Stuttgart, Stuttgart, Fed. Rep. Ger.
SO Chemische Berichte (1972), 105(6), 1926-42
CODEN: CHBEAM; ISSN: 0009-2940
DT Journal
LA German
OS CASREACT 77:61917
GI For diagram(s), see printed CA Issue.
AB Thermal rearrangement of N-aryl-substituted m-RC6H4O2CNHR1 (I, R = pyrrolidinyl, piperidino, or Me2N; R1 = Ph, Bz, or p-ClC6H4CO) obtained from m-RC6H4OH and R1NCO gave 4,2-R(HO)C6H3-CONHR1 (II), whereas N-alkoxy-substituted I gave 2,4-dioxo-3,4-dihydro-2H-1,3-benzoxazines (III). III were cleaved by dilute KOH with CO2 evolution to give II (R1 = H). The mechanism of this Fries rearrangement-like reaction involving an intramol. path is discussed.
IT 37893-35-9P 37893-36-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37893-35-9 HCAPLUS
CN Benzamide, N-benzoyl-2-hydroxy-4-(1-piperidinyl)- (CA INDEX NAME)



RN 37893-36-0 HCAPLUS
CN Benzamide, N-(4-chlorobenzoyl)-2-hydroxy-4-(1-piperidinyl)- (CA INDEX NAME)



L25 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1959:33464 HCAPLUS
DN 53:33464
OREF 53:5932e-i
TI Substituted benzoylacetanilide color couplers
IN Corby, Neville S.; Haddock, Norman H.
PA Imperial Chemical Industries Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB------805505		19581210	1956GB-0000015799	19560522 <--

AB Color couplers are produced by the condensation of substituted benzoylacetanilides with esters. Thus, 3-amino-4-(N-methyl-N-octadecylamino)benzoic acid 11 is heated to 130° in PhCl and a solution of Et dimethylaminobenzoylacetate 6.4 in PhCl 20 and pyridine 1 part is slowly added. The solution is heated and 27 parts of a mixture of EtOH and PhCl is distilled off, refluxed for 2 hrs., and more PhCl distilled The reaction mixture is cooled and the anilide filtered and washed with boiling EtOH to yield p-dimethylaminobenzoylacet-2-(N-methyl-N-octadecylamino)-5-carboxyanilide, m. 159-61° (from BuOH). Similarly, p-(N-benzyl-N-ethylamino)benzoylacet-2-(N-methyl-N-octadecylamino)-5-carboxyanilide, m. 125-7°, p-dimethylaminobenzoylacet-2-(N-methyl-N-hexadecylamino)-5-carboxyanilide, m. 164-6° are obtained. In addition, p-dimethylaminobenzoylacet-2-dimethylamino-5-carboxyanilide, m. 195-6° (from dioxane); p-dimethylaminobenzoylacet-5-diethylsulfamoyl-2-methoxyanilide, m. 135-7° (from C6H6-petr. ether); p-dimethylaminobenzoylacet-2-chloro-5-trifluoromethylanilide, m. 193-5° (from MeOH); p-dimethylaminobenzoylacet-2,5-dimethoxyanilide, m. 143-5° (from MeOH); p-dimethylaminobenzoylacet-4-(4-chlorophenoxy)anilide, m. 180-3°; p-dimethylaminobenzoylacet-o-toluidide, m. 158-60° (from MeOH); p-dimethylaminobenzoylacetanilide-4-sulfonic acid, m. 220-3° (decomposition) (from aqueous EtOH); p-dimethylaminobenzoylacet-4-nitroaniline, m. 220-2° (from EtOH); p-dimethylaminobenzoylacet-4-aminoanilide, m. 169-70° (from MeOH); p-piperidinobenzoylacet-2-(N-methyl-N-octadecylamino)-5-carboxyanilide, m. 155-7° (from BuOH); p-(N-methyl-N-phenylamino)benzoylacet-2-(N-methyl-N-octadecylamino)-5-carboxyanilide, m. 137-9° (from Me2CO); p-(N-benzyl-N-ethylamino)benzoyl-α-chloroacet-2-(N-methyl-N-octadecylamino)-5-carboxyanilide, m. 119-21° (from EtOH); and p-(dimethylamino)benzoylacet-4-(α-carboxymethylene-α-octadecenylacetamido)anilide, m. 139-42° (from MeOH); are obtained in similar reactions. The couplers are used to produce color images when incorporated in a light-sensitive gelatin-Ag halide emulsion.
IT 103402-24-0P, Benzoic acid, 4-(methyloctadecylamino)-3-(2-p-piperidinobenzoylacetamido)-
RL: PREP (Preparation)
(manufacture and use as color coupler)
RN 103402-24-0 HCAPLUS
CN Benzoic acid, 4-(methyloctadecylamino)-3-(2-p-piperidinobenzoylacetamido)- (6CI) (CA INDEX NAME)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 15:45:52 ON 12 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 15:45:52 ON 12 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:45:52 ON 12 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l31 tot
```

L31 ANSWER 1 OF 2 USPATFULL on STN
AN 2008:117902 USPATFULL
TI METHOD FOR FABRICATING A SEMICONDUCTOR STRUCTURE
IN Meister, Thomas, Taufkirchen, GERMANY, FEDERAL REPUBLIC OF
Schafer, Herbert, Hohenkirchen-Siegertsbrunn, GERMANY, FEDERAL REPUBLIC OF
Bock, Josef, Munich, GERMANY, FEDERAL REPUBLIC OF
Lachner, Rudolf, Ingolstadt, GERMANY, FEDERAL REPUBLIC OF
PA INFINEON TECHNOLOGIES AG, Muenchen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US-20080102593 A1 20080501
AI 2006US-000553704 A1 20061027 (11)
DT Utility
FS APPLICATION
LREP DICKE, BILLIG & CZAJA, FIFTH STREET TOWERS, 100 SOUTH FIFTH STREET, SUITE 2250, MINNEAPOLIS, MN, 55402, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for fabricating a semiconductor including defining a first component region and a second component region in a semiconductor body is provided. A first epitaxial layer is formed through the first component region. A second epitaxial layer is formed over the first epitaxial layer, including configuring the physical dimensions of a first active zone of the first component region independent of a second active zone of the second component region via the first epitaxial layer and the second epitaxial layer. In one embodiment, the first component is a radio-frequency transistor and the second component is a varactor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 783345-29-9P 783345-30-2P 783345-31-3P
783345-32-4P 783345-33-5P 783345-34-6P
783345-35-7P 783345-36-8P 783345-37-9P
783345-38-0P 783345-39-1P 783345-40-4P
783345-41-5P 783345-42-6P 783345-43-7P
783345-44-8P 783345-45-9P 783345-46-0P
783345-47-1P 783345-48-2P 783345-49-3P
783345-50-6P 783345-51-7P 783345-52-8P
783345-69-7P 783345-70-0P 783345-74-4P
783345-75-5P 783345-76-6P 783345-77-7P
783345-78-8P 783345-79-9P 783345-80-2P
783345-81-3P 783345-82-4P 783345-83-5P
783345-84-6P 783345-85-7P 783345-86-8P
783345-87-9P 783345-88-0P 783345-89-1P
783345-90-4P 783345-91-5P 783345-92-6P
783346-39-4P 783346-40-7P 783346-41-8P
783346-42-9P 783346-43-0P 783346-44-1P
783346-45-2P 783346-46-3P 783346-47-4P
783346-48-5P 783346-49-6P 783346-50-9P
783346-51-0P 783346-52-1P 783346-53-2P
783346-54-3P 783346-55-4P 783346-56-5P
783346-57-6P 783346-58-7P 783346-59-8P
783346-60-1P 783346-61-2P 783346-62-3P
783346-63-4P 783346-64-5P 783346-65-6P
783346-66-7P 783346-68-9P 783346-69-0P
783346-70-3P 783346-71-4P 783346-72-5P
783346-73-6P 783346-74-7P 783346-75-8P
783347-15-9P 783347-16-0P 783347-44-4P
783347-47-7P 783347-48-8P 783347-49-9P
783347-50-2P 783347-51-3P 783347-53-5P
783347-54-6P 783347-55-7P 783347-56-8P
783347-57-9P 783347-58-0P 783347-59-1P
783347-63-7P 783347-65-9P 783347-66-0P
783347-67-1P 783347-68-2P 783347-73-9P
783347-74-0P 783347-75-1P 783347-76-2P
783347-77-3P 783347-78-4P 783347-79-5P
783347-80-8P 783347-81-9P 783347-82-0P
783347-82-1P 783347-84-2P 783347-85-3P
783347-86-4P 783347-89-7P 783347-90-0P

L31 ANSWER 1 OF 2 USPATFULL on STN (Continued)
783347-91-1P 783347-92-2P 783347-93-3P
783347-94-4P 783347-95-5P 783347-96-6P
783347-98-8P 783347-99-9P 783348-00-5P
783348-16-3P 783348-18-5P 783348-19-6P
(drug candidate; prepn. of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)
IT 783345-29-9P
(drug candidate; preparation of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)
RN 783345-29-9 USPATFULL
CN Benzamide, N-[[3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]-4-(methylthio)- (CA INDEX NAME)



L31 ANSWER 2 OF 2 USPATFULL on STN
AN 2007:49253 USPATFULL
TI Heterocyclic compound containing nitrogen atom and use thereof
IN Habashita, Hiromu, Mishima-gun, JAPAN
Nishizaki, Minoru, Mishima-gun, JAPAN
Hayashi, Kazuya, Sakai-gun, JAPAN
Shibayama, Shiro, Tsukuba-shi, JAPAN
PI US-20070043079 A1 20070222
AI 2004US-000553704 A1 20040416 (10)
2004WO-JP0005504 20040416
20060905 PCT 371 date
PRAI 2003JP-000114172 20030418
2003JP-000346384 20031030
DT Utility
FS APPLICATION
LREP SUGHRUE-265550, 2100 PENNSYLVANIA AVE. NW, WASHINGTON, DC, 20037-3213, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a medicament comprising the compound of formula (I) ##STR1## wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 783345-29-9P 783345-30-2P 783345-31-3P
783345-32-4P 783345-33-5P 783345-34-6P
783345-35-7P 783345-36-8P 783345-37-9P
783345-38-0P 783345-39-1P 783345-40-4P
783345-41-5P 783345-42-6P 783345-43-7P
783345-44-8P 783345-45-9P 783345-46-0P
783345-47-1P 783345-48-2P 783345-49-3P
783345-50-6P 783345-51-7P 783345-52-8P
783345-69-7P 783345-70-0P 783345-74-4P
783345-75-5P 783345-76-6P 783345-77-7P
783345-78-8P 783345-79-9P 783345-80-2P
783345-81-3P 783345-82-4P 783345-83-5P
783345-84-6P 783345-85-7P 783345-86-8P
783345-87-9P 783345-88-0P 783345-89-1P
783345-90-4P 783345-91-5P 783345-92-6P
783346-39-4P 783346-40-7P 783346-41-8P
783346-42-9P 783346-43-0P 783346-44-1P
783346-45-2P 783346-46-3P 783346-47-4P
783346-48-5P 783346-49-6P 783346-50-9P
783346-51-0P 783346-52-1P 783346-53-2P
783346-54-3P 783346-55-4P 783346-56-5P
783346-57-6P 783346-58-7P 783346-59-8P
783346-60-1P 783346-61-2P 783346-62-3P
783346-63-4P 783346-64-5P 783346-65-6P
783346-66-7P 783346-68-9P 783346-69-0P
783346-70-3P 783346-71-4P 783346-72-5P
783346-73-6P 783346-74-7P 783346-75-8P
783347-15-9P 783347-16-0P 783347-44-4P
783347-47-7P 783347-48-8P 783347-49-9P
783347-50-2P 783347-51-3P 783347-53-5P
783347-54-6P 783347-55-7P 783347-56-8P
783347-57-9P 783347-58-0P 783347-59-1P
783347-63-7P 783347-65-9P 783347-66-0P
783347-67-1P 783347-68-2P 783347-73-9P

L31 ANSWER 2 OF 2 USPATFULL on STN (Continued)
783347-74-0P 783347-75-1P 783347-76-2P
783347-77-3P 783347-78-4P 783347-79-5P
783347-80-8P 783347-81-9P 783347-82-0P
783347-83-1P 783347-84-2P 783347-85-3P
783347-86-4P 783347-89-7P 783347-90-0P
783347-91-1P 783347-92-2P 783347-93-3P
783347-94-4P 783347-95-5P 783347-96-6P
783347-98-8P 783347-99-9P 783348-00-5P
783348-16-3P 783348-18-5P 783348-19-6P
(drug candidate; prepn. of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)
IT 783345-29-9P
(drug candidate; preparation of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)
RN 783345-29-9 USPATFULL
CN Benzamide, N-[[3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]-4-(methylthio)- (CA INDEX NAME)



=> => d bib abs hitstr l40 tot

L40 ANSWER 1 OF 2 USPATFULL on STN
AN 2008:117902 USPATFULL
TI METHOD FOR FABRICATING A SEMICONDUCTOR STRUCTURE
IN Meister, Thomas, Taufkirchen, GERMANY, FEDERAL REPUBLIC OF
Schafer, Herbert, Hohenkirchen-Siegertsbrunn, GERMANY, FEDERAL REPUBLIC OF
Bock, Josef, Munich, GERMANY, FEDERAL REPUBLIC OF
Lachner, Rudolf, Ingolstadt, GERMANY, FEDERAL REPUBLIC OF
PA INFINEON TECHNOLOGIES AG, Muenchen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US-20080102593 A1 20080501
AI 2006US-000553704 A1 20061027 (11)
DT Utility
FS APPLICATION
LREP DICKE, BILLIG & CZAJA, FIFTH STREET TOWERS, 100 SOUTH FIFTH STREET, SUITE 2250, MINNEAPOLIS, MN, 55402, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for fabricating a semiconductor including defining a first component region and a second component region in a semiconductor body is provided. A first epitaxial layer is formed through the first component region. A second epitaxial layer is formed over the first epitaxial layer, including configuring the physical dimensions of a first active zone of the first component region independent of a second active zone of the second component region via the first epitaxial layer and the second epitaxial layer. In one embodiment, the first component is a radio-frequency transistor and the second component is a varactor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 783345-41-5P 783345-51-7P 783347-53-5P
783347-54-6P 783348-16-3P
(drug candidate; preparation of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)
RN 783345-41-5 USPATFULL
CN Benzamide, N-[[3-[[1-[(2-chlorophenyl)methyl]-4-piperidinyl]phenyl]methyl]-2,4-dimethoxy- (CA INDEX NAME)



RN 783345-51-7 USPATFULL
CN Benzamide, N-[[3-[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]phenyl]methyl]-2,4-dimethoxy- (CA INDEX NAME)



RN 783347-53-5 USPATFULL
CN Benzamide, 2-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)

L40 ANSWER 1 OF 2 USPATFULL on STN (Continued)



RN 783347-54-6 USPATFULL
CN Benzamide, 3-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 783348-16-3 USPATFULL
CN Benzamide, 4-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L40 ANSWER 2 OF 2 USPATFULL on STN
AN 2007:49253 USPATFULL
TI Heterocyclic compound containing nitrogen atom and use thereof
IN Habashita, Hiromu, Mishima-gun, JAPAN
Nishizaki, Minoru, Mishima-gun, JAPAN
Hayashi, Kazuya, Sakai-gun, JAPAN
Shibayama, Shiro, Tsukuba-shi, JAPAN
PI US-20070043079 A1 20070222
AI 2004US-000553704 A1 20040416 (10)
2004WO-JP0005504 20040416
20060905 PCT 371 date
PRAI 2003JP-000114172 20030418
2003JP-000346384 20031030
DT Utility
FS APPLICATION
LREP SUGHRUE-265550, 2100 PENNSYLVANIA AVE. NW, WASHINGTON, DC, 20037-3213, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a medicament comprising the compound of formula (I) ##STR1## wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 783345-41-5P 783345-51-7P 783347-53-5P
783347-54-6P 783348-16-3P
(drug candidate; preparation of N-[(piperidinyl)benzyl]benzamide derivs. as chemokine receptor antagonists)
RN 783345-41-5 USPATFULL
CN Benzamide, N-[[3-[[1-[(2-chlorophenyl)methyl]-4-piperidinyl]phenyl]methyl]-2,4-dimethoxy- (CA INDEX NAME)



RN 783345-51-7 USPATFULL
CN Benzamide, N-[[3-[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]phenyl]methyl]-2,4-dimethoxy- (CA INDEX NAME)



L40 ANSWER 2 OF 2 USPATFULL on STN (Continued)
RN 783347-53-5 USPATFULL
CN Benzamide, 2-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 783347-54-6 USPATFULL
CN Benzamide, 3-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 783348-16-3 USPATFULL
CN Benzamide, 4-chloro-N-[[4-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

=> d bib abs hitstr l37 tot

L37 ANSWER 1 OF 28 USPATFULL on STN
AN 2007:142263 USPATFULL
TI Online charging in a communications network
IN Watson, Mark, London, UNITED KINGDOM
Richards, Christopher, Dallas, TX, UNITED STATES
Ricagni, Giuseppe, Milano, ITALY
Mclean, Ian, Dallas, TX, UNITED STATES
PI US-20070124254 A1 20070531
AI 2004US-000555914 A1 20040428 (10)
2004WO-GB0001815 20040428
20061023 PCT 371 date
PRAI 2003EP-000076426 20030507 <--
DT Utility
FS APPLICATION
LREP BARNES & THORNBURG LLP, P.O. BOX 2786, CHICAGO, IL, 60690-2786, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1-63
DRWN 10 Drawing Page(s)
LN.CNT 1312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A communications network in which service flows between an end user and the network are transported via a gateway (8) which identifies different service flows and notifies them to a credit control function (12) of the network. The credit control function grants a cache representing an amount of and end user's credit and/or an amount of network resource to the gateway for the identified service flows and provides instructions to the gateway for the identified service flows which enable the gateway to share units of the caches between service flows, for example if there is a threat of a service flow becoming blocked due to a lack of credit in an end user's account.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPATFULL
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 2 OF 28 USPATFULL on STN
AN 2007:62743 USPATFULL
TI NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., North Wales, PA, UNITED STATES
PI US-20070054888 A1 20070308
AI 2006US-000555914 A1 20061102 (11)
RLI Division of Ser. No. 2006US-000386960, filed on 26 Apr 2006, GRANTED, Pat. No. US-----7166601 Division of Ser. No. 2005US-000066202, filed on 25 Feb 2005, GRANTED, Pat. No. US-----7112586 Division of Ser. No. 2002US-000291133, filed on 8 Nov 2002, GRANTED, Pat. No. US-----6967199 Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, GRANTED, Pat. No. US-----6511980
PRAI 2000US-000202131P 20000505 (60) <--
DT Utility
FS APPLICATION
LREP PHILLIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPATFULL
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 3 OF 28 USPATFULL on STN
AN 2007:49250 USPATFULL
TI Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Pervin, Azra, Murrieta, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Nguyen, Bao Ngoc, San Diego, CA, UNITED STATES
PI US-20070043076 A1 20070222
AI 2004US-000572910 A1 20041005 (10)
2004WO-US0032570 20041005
20060321 PCT 371 date
PRAI 2003US-000508290P 20031006 (60) <--
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3795
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs thereof. The present invention also relates to the discovery that the compounds are activators of caspases and inducers of apoptosis. Therefore, the activators os caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 850798-12-8P
(drug candidate; preparation of 2-arylmethylene-N,N'-diarylmalonamides and analogs as activators of caspases and inducers of apoptosis)
RN 850798-12-8 USPATFULL
CN Propanediamide, 2-[[4-(4-methyl-1-piperidinyl)phenyl]methylene]-N1,N3-bis[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L37 ANSWER 4 OF 28 USPATFULL on STN
AN 2006:248314 USPATFULL
TI Protein kinase modulators and methods of use
IN Buhr, Chris A., Redwood City, CA, UNITED STATES
Baik, Tae-Gon, Foster City, CA, UNITED STATES
Ma, Sunghoon, Foster City, CA, UNITED STATES
Tesfai, Zerom, San Leandro, CA, UNITED STATES
Wang, Longcheng, South San Francisco, CA, UNITED STATES
Co, Erick Wang, Redwood City, CA, UNITED STATES
Epshteyn, Sergey, Fremont, CA, UNITED STATES
Kennedy, Abigail R., San Leandro, CA, UNITED STATES
Chen, Baili, Palo Alto, CA, UNITED STATES
Dubenko, Larisa, San Francisco, CA, UNITED STATES
Anand, Neel Kumar, Burlingame, CA, UNITED STATES
Tsang, Tsze H., El Cerrito, CA, UNITED STATES
Nuss, John M., Danville, CA, UNITED STATES
Peto, Csabaj, Alameda, CA, UNITED STATES
Rice, Kenneth D., Mill Valley, CA, UNITED STATES
Ibrahim, Mohamed Abdulkader, Mountain View, CA, UNITED STATES
Shi, Xian, San Bruno, CA, UNITED STATES
Leahy, James William, San Leandro, CA, UNITED STATES
Chen, Jeff, San Francisco, CA, UNITED STATES
Dalrymple, Lisa Esther, San Francisco, CA, UNITED STATES
Forsyth, Timothy Patrick, Hayward, CA, UNITED STATES
Huynh, Tai Phat, Oakland, CA, UNITED STATES
Mann, Grace, Brisbane, CA, UNITED STATES
Mann, Larry Wayne, Redwood City, CA, UNITED STATES
Takeuchi, Craig Stacy, Burlingame, CA, UNITED STATES
PI US-20060211709 A1 20060921
AI 2003US-000513081 A1 20030502 (10) <--
2003WO-US0013869 20030502 <--
20050727 PCT 371 date
PRAI 2003DE-000000103 20030109 <--
2002US-000377933P 20020503 (60) <--
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, US
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 625463-00-5P
(preparation of protein kinase modulators)
RN 625463-00-5 USPATFULL
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-(1-piperidinyl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



L37 ANSWER 5 OF 28 USPATFULL on STN
AN 2006:215585 USPATFULL
TI Novel substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., North Wales, PA, UNITED STATES
PI US-20060183741 A1 20060817
US------7166601 B2 20070123
AI 2006US-000386960 A1 20060426 (11)
RLI Division of Ser. No. 2005US-000066202, filed on 25 Feb 2005, PENDING
Division of Ser. No. 2002US-000291133, filed on 8 Nov 2002, GRANTED, Pat. No. US------6967199 Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, GRANTED, Pat. No. US------6511980
PRAI 2000US-000202131P 20000505 (60) <--
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
CLMN Number of Claims: 4
ECL Exemplary Claims: 1-35
DRWN No Drawings
LN.CNT 2434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPATFULL
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 6 OF 28 USPATFULL on STN
AN 2006:189424 USPATFULL
TI Acrylamide derivative, process for producing the same, and use
IN Shiraishi, Mitsuru, Osaka, JAPAN
Seto, Masaki, Osaka, JAPAN
Aikawa, Katsuji, Osaka, JAPAN
Kanzaki, Naoyuki, Osaka, JAPAN
Baba, Masanori, Kagoshima, JAPAN
PI US-20060160864 A1 20060720
AI 2004US-000544275 A1 20040202 (10) <--
2004WO-JP0001181 20040202 <--
20050901 PCT 371 date
PRAI 2003JP-000031068 20030207 <--
DT Utility
FS APPLICATION
LREP Mark Chao, Takeda Pharmaceuticals North America Inc, Intellectual Property Department, 475 Half Day Road Suite 500, Lincolnshire, IL, 60069, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound represented by the formula: ##STR1## wherein R.sup.1 is a 5- or 6-membered ring; R.sup.3 is a hydrogen atom, a lower alkyl group or a lower alkoxy group; R.sup.7 and R.sup.8 are each a hydrogen atom or a lower alkyl group; Z.sup.1 is another 5- or 6-membered aromatic ring; Z.sup.2 is a group represented by -Z.sup.2a-W.sup.1-Z.sup.2b- [wherein Z.sup.2a and Z.sup.2b are each O, S(O).sub.m (wherein m is 0, 1 or 2), an imino group or a bond, and W.sup.1 is an alkylene chain]; X is CR (wherein R is a hydrogen atom, a lower alkyl group, a lower alkoxy group, an acyl group, or R and adjacent R.sup.4 may form a 5- or 6-membered alicyclic heterocyclic group) or N; R.sup.4 is NR.sup.5R.sup.6 (wherein R.sup.5 and R.sup.6 are each a hydrogen atom, a hydrocarbon group, a heterocyclic group or an acyl group), or R.sup.5 and R.sup.6 are bonded to each other to form a heterocyclic group of NR.sup.5R.sup.6; and R.sup.2 is (1) an amino group which may be a quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or the like; or a salt thereof. The compound has excellent CCR5 antagonistic activity and thus is useful as a prophylactic and/or therapeutic medicine for HIV infection into human peripheral blood monocyte, especially for AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 742098-55-1P 742098-56-2P 742098-59-5P
742098-60-8P 742098-66-4P 742098-67-5P
(preparation of acrylamide derivs. as CCR antagonists)
RN 742098-55-1 USPATFULL
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

L37 ANSWER 6 OF 28 USPATFULL on STN (Continued)



RN 742098-56-2 USPATFULL
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(1-piperidinyl)[1,1'-biphenyl]-3-yl]-2-methyl-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 742098-59-5 USPATFULL
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(4-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L37 ANSWER 6 OF 28 USPATFULL on STN (Continued)



RN 742098-60-8 USPATFULL
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(4-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-2-methyl-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 742098-66-4 USPATFULL
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(3-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L37 ANSWER 6 OF 28 USPATFULL on STN (Continued)



RN 742098-67-5 USPATFULL
CN 2-Propenamide, 3-[4'-(2-butoxyethoxy)-4-(2-methyl-1-piperidinyl)[1,1'-biphenyl]-3-yl]-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L37 ANSWER 7 OF 28 USPATFULL on STN

AN 2006:93402 USPATFULL
TI Methods of treating alzheimer's disease
IN Nieman, James A., 287 IIene Street, Galesburg, MI, UNITED STATES 49053
Fang, Lawrence, Foster City, CA, UNITED STATES
Jagodzinska, barbara, Redwood City, CA, UNITED STATES
PI US-20060079533 A1 20060413
AI 2002US-000472868 A1 20020321 (10) <--
2002WO-US0009100 20020321 <--
20040202 PCT 371 date
PRAI 2001US-000278371P 20010323 (60) <--
2001US-000308729P 20010730 (60) <--
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of 3,4-disubstituted piperidinyl compounds of formula (I) wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, W, X, Z, m, and n are defined herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 188863-69-6P, Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel-
188863-71-0P, Benzamide, N-[[4-[3-[(4-hydroxy-2-naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, trans-
(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes)
RN 188863-69-6 USPATFULL
CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-71-0 USPATFULL
CN Benzamide, N-[[4-[(3R,4R)-3-[(4-hydroxy-2-naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L37 ANSWER 7 OF 28 USPATFULL on STN (Continued)



IT 188863-75-4P, 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, trans- 188863-77-6P, 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[[2-(trimethylsilyl)ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, trans-
(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes)
RN 188863-75-4 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-77-6 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[[2-(trimethylsilyl)ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 7 OF 28 USPATFULL on STN (Continued)

L37 ANSWER 8 OF 28 USPATFULL on STN
AN 2005:177941 USPATFULL
TI 4-aryl piperidines
IN Marzabadi, Mohammad R., Ridgewood, NJ, UNITED STATES
Wetzel, John M., Fairlawn, NJ, UNITED STATES
Chen, Chien-An, Flushing, NY, UNITED STATES
DeLeon, John E., North Bergen, NJ, UNITED STATES
Jiang, Yu, Jersey City, NJ, UNITED STATES
Lu, Kai, Lake Hiawatha, NJ, UNITED STATES
PA H. Lundbeck A/S (U.S. corporation)
PI US-20050154022 A1 20050714
AI 2005US-000034611 A1 20050113 (11)
PRAI 2004US-000536585P 20040114 (60) <--
DT Utility
FS APPLICATION
LREP LUNDBECK RESEARCH USA, INC., ATTENTION: STEPHEN G. KALINCHAK, LEGAL, 215 COLLEGE ROAD, PARAMUS, NJ, 07652, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 859170-25-5P 859170-27-7P
(preparation of arylpiperidines as selective antagonists for melanin concentrating hormone-1 receptors)
RN 859170-25-5 USPATFULL
CN Benzenebutanamide, N-[4-methyl-3-(4-piperidinyl)phenyl]-4-(2-pyridinyl)- (CA INDEX NAME)



RN 859170-27-7 USPATFULL
CN Benzenepentanamide, N-[4-methyl-3-(4-piperidinyl)phenyl]-4-(4-pyridinyl)- (CA INDEX NAME)



L37 ANSWER 8 OF 28 USPATFULL on STN (Continued)

L37 ANSWER 9 OF 28 USPATFULL on STN
AN 2005:171835 USPATFULL
TI Novel substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., North Wales, PA, UNITED STATES
PI US-20050148584 A1 20050707
US-----7112586 B2 20060926
AI 2005US-000066202 A1 20050225 (11)
RLI Division of Ser. No. 2002US-000291133, filed on 8 Nov 2002, PENDING
Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, GRANTED, Pat. No. US-----6511980
PRAI 2000US-000202131P 20000505 (60) <--
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-13
DRWN No Drawings
LN.CNT 2837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPATFULL
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 10 OF 28 USPATFULL on STN
AN 2004:133894 USPATFULL
TI Substituted amino-aza-cycloalkanes useful against malaria
IN Boss, Christoph, Allschwil, SWITZERLAND
Fischli, Walter, Allschwil, SWITZERLAND
Meyer, Solange, Schlierbach, FRANCE
Richard-Bildstein, Sylvia, Rixheim, FRANCE
Weller, Thomas, Binningen, SWITZERLAND
PI US-20040102431 A1 20040527
AI 2003US-000381567 A1 20030325 (10) <--
2001WO-EP0010272 20010906 <--
PRAI 2000WO-EP0009328 20000925 <--
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST STREET, NEW YORK, NY, 10017
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1077
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel compounds which are substituted amino-aza-cycloalkane derivatives of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of the plasmodium falciparum protease plasmepsin II or related aspartic proteases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405513-81-7P 405513-87-3P 405513-89-5P
405513-96-4P 405514-03-6P 405514-06-9P
405514-08-1P 405514-09-2P 405514-12-7P
405514-14-9P 405514-15-0P 405514-20-7P
405514-21-8P 405514-26-3P 405514-27-4P
405514-64-9P 405514-65-0P 405514-66-1P
(drug; preparation of substituted amino-aza-cycloalkanes as anti-malarial agents)
RN 405513-81-7 USPATFULL
CN Benzamide, N-[1-(3-methylbutyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405513-87-3 USPATFULL
CN Benzamide, 4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]-N-[1-(3-thienylmethyl)-4-piperidinyl]- (CA INDEX NAME)

L37 ANSWER 10 OF 28 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 405513-89-5 USPATFULL
CN Benzamide, N-[1-(cyclohexylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405513-96-4 USPATFULL
CN Benzamide, N-[1-(3-furanylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L37 ANSWER 10 OF 28 USPATFULL on STN (Continued)



RN 405514-08-1 USPATFULL
CN Benzamide, 4-pentyl-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-09-2 USPATFULL
CN Benzamide, N-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-12-7 USPATFULL
CN Benzamide, N-[1-(1-cyclohexen-1-ylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-14-9 USPATFULL
CN Benzamide, N-[1-[[5-(hydroxymethyl)-2-furanyl]methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L37 ANSWER 10 OF 28 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 405514-03-6 USPATFULL
CN Benzamide, N-[1-(1-cyclohexen-1-ylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-06-9 USPATFULL
CN Benzamide, 4-pentyl-N-[1-(4-pyridinylmethyl)-4-piperidinyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L37 ANSWER 10 OF 28 USPATFULL on STN (Continued)



RN 405514-15-0 USPATFULL
CN Benzamide, N-[1-(cyclopropylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-20-7 USPATFULL
CN Benzamide, N-[1-(3-furanylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



L37 ANSWER 10 OF 28 USPATFULL on STN (Continued)

PAGE 2-A

RN 405514-21-8 USPATFULL
CN Benzamide, 4-pentyl-N-[1-(4-pyridinylmethyl)-4-piperidinyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-26-3 USPATFULL
CN Benzamide, 4-pentyl-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-27-4 USPATFULL
CN Benzamide, N-[1-(2-benzofuranylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-64-9 USPATFULL
CN Benzamide, 4-pentyl-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L37 ANSWER 10 OF 28 USPATFULL on STN (Continued)



RN 405514-65-0 USPATFULL
CN Benzamide, N-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 405514-66-1 USPATFULL
CN Benzamide, N-[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]-4-pentyl-N-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



L37 ANSWER 11 OF 28 USPATFULL on STN
AN 2003:319310 USPATFULL
TI Cyclohexyl derivatives and their use as therapeutic agents
IN Pineiro, Jose Luis Castro, Bishops Stortford, UNITED KINGDOM
Dinnell, Kevin, Much Hadham, UNITED KINGDOM
Elliott, Jason Matthew, Felsted, UNITED KINGDOM
Hollingworth, Gregory John, Brentwood, UNITED KINGDOM
Shaw, Duncan Edward, Bishops Stortford, UNITED KINGDOM
Swain, Christopher John, Dunford, UNITED KINGDOM
Yang, Lihu, Edison, NJ, UNITED STATES

PI	US-20030225059	A1	20031204	<--
	US-----6953792	B2	20051011	
AI	2002US-000276129	A1	20021113 (10)	<--
	2001WO-GB0002136		20010516	
PRAI	2000GB-000012214		20000519	<--

DT Utility
FS APPLICATION
LREP Merck & Co Inc, 126 East Lincoln Avenue, Rahway, NJ, 07065
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R?17, R.sup.18, R.sup.19, R.sup.21a and R.sup.21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. ##STR1## ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 374821-73-5P
(preparation of cyclohexane derivs. for therapeutic use in the treatment of disorders, such as depression, anxiety, pain, inflammation, migraine, and vomiting)
RN 374821-73-5 USPATFULL
CN Benzamide, N-[[trans-4-[4-(4-fluorophenyl)-1-piperidinyl]-1-phenylcyclohexyl]methyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 12 OF 28 USPATFULL on STN
AN 2003:312713 USPATFULL
TI New phenylalanine derivatives
IN Suzuki, Nobuyasu, Kawasaki-shi, JAPAN
Yoshimura, Toshihiko, Kawasaki-shi, JAPAN
Izawa, Hiroyuki, Kawasaki-shi, JAPAN
Sagi, Kazuyuki, Kawasaki-shi, JAPAN
Makino, Shingo, Kawasaki-shi, JAPAN
Nakanishi, Eiji, Kawasaki-shi, JAPAN
Murata, Masahiro, Kawasaki-shi, JAPAN
Tsuji, Takashi, Kawasaki-shi, JAPAN
PA AJINOMOTO CO. INC, Tokyo, JAPAN (non-U.S. corporation)

PI	US-20030220318	A1	20031127	<--
AI	2003US-000402006	A1	20030331 (10)	<--

RLI Continuation of Ser. No. 2001WO-JP008489, filed on 28 Sep 2001, UNKNOWN

PRAI	2000JP-000299490	20000929	<--
	2001JP-000041885	20010219	<--

DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Specific phenylalanine derivatives or pharmaceutically acceptable. salts thereof have an antagonistic effect on the α4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 409126-83-6P 409126-84-7P 409126-85-8P
(preparation of phenylalanine derivs. as inhibitors of integrin α4 and remedies or preventives for inflammatory diseases)
RN 409126-83-6 USPATFULL
CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-(3,3-dimethyl-2,6-dioxo-1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 409126-84-7 USPATFULL
CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-[(3R)-2,6-dioxo-3-phenyl-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L37 ANSWER 12 OF 28 USPATFULL on STN (Continued)



RN 409126-85-8 USPATFULL
CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 13 OF 28 USPATFULL on STN
AN 2003:289147 USPATFULL
TI Novel substituted diamine derivatives useful as motlin antagonists
IN Johnson, Sigmong G., Three Bridges, NJ, UNITED STATES
Rivero, Ralph A., Noth Wales, PA, UNITED STATES
PI US-20030203906 A1 20031030 <--
US-----6967199 B2 20051122
AI 2002US-000291133 A1 20021108 (10) <--
RLI Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, GRANTED, Pat. No. US-----6511980
PRAI 2000US-0002021319P 20000505 (60) <--
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPATFULL
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 14 OF 28 USPATFULL on STN
AN 2002:246745 USPATFULL
TI Adhesion receptor antagonists
IN Gante, Joachim, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Juraszyk, Horst, Seeheim, GERMANY, FEDERAL REPUBLIC OF
Raddatz, Peter, Seeheim, GERMANY, FEDERAL REPUBLIC OF
Wurziger, Hanns, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Bernotat-Danielowski, Sabine, Bad Nauheim, GERMANY, FEDERAL REPUBLIC OF
Melzer, Guido, Hofheim/Ts, GERMANY, FEDERAL REPUBLIC OF
PA Merck Patent Gesellschaft mit beschraenkter Haftung, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US-----6455529 B1 20020924 <--
AI 1996US-000642268 19960503 (8) <--
PRAI 1995DE-100016483 19950505 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP Millen, White, Zelano & Branigan, P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula I ##STR1##

in which R.sup.1, R.sup.2 and R.sup.3 have the stated meanings, and their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporoses, oncoses, stroke, myocardial infarct, ischemias, inflammations, arteriosclerosis and osteolytic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184634-48-8P
(preparation of N-[(acylamidino)phenyl]oxazolidinones and analogs as adhesion receptor antagonists)
RN 184634-48-8 USPATFULL
CN [1,4'-Bipiperidine]-4-carboxylic acid, 1'-[4-[(benzoylamino)iminomethyl]phenyl]-, ethyl ester (CA INDEX NAME)



L37 ANSWER 15 OF 28 USPATFULL on STN
AN 2002:239024 USPATFULL
TI N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders
IN Howard, Harry R., Bristol, CT, United States
PA Pfizer INC, New York, NY, United States (U.S. corporation)
PI US-----6451803 B1 20020917 <--
AI 2000US-000583691 20000531 (9) <--
RLI Division of Ser. No. 1999US-000291454, filed on 14 Apr 1999, now patented, Pat. No. US-----6323229
PRAI 1998US-000081970P 19980416 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a compound of the formula ##STR1##

wherein m, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X are as defined in the disclosure, for treating or preventing migraine, depression and other disorders for which a 5-HT.sub.1 agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 247157-70-6P 247157-80-8P
(preparation of N-acyl and N-aroyl aralkyl amides as 5-HT1 agonists or antagonists)
RN 247157-70-6 USPATFULL
CN Benzamide, 3,4-dichloro-N-[2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]- (CA INDEX NAME)

RN 247157-80-8 USPATFULL
CN Benzamide, N-[2-[2-(1,4-dimethyl-4-piperidinyl)phenyl]ethyl]-4-fluoro- (CA INDEX NAME)

L37 ANSWER 16 OF 28 USPATFULL on STN
AN 2002:58690 USPATFULL
TI Noise-adaptive packet envelope detection
IN Calderone, Theodore, San Carlos, CA, United States
PA Diva Systems Corporation, Redwood City, CA, United States (U.S. corporation)
PI US------6359939 B1 20020319 <--
AI 1998US-000081970 19980520 (9) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chin, Stephen; Assistant Examiner: Liu, Shuwang
LREP Moser, Patterson & Sheridan, LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and concomitant apparatus for adapting a logic threshold level in response to a background noise level in an information signal. Information signal excursions beyond the logic threshold are indicative of the presence of an information packet in the information signal. In this manner, a relatively low dynamic range information packet processor may reliably receive information packets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 247157-70-6P 247157-80-8P
(preparation of N-acyl and N-aroyl aralkyl amides as 5-HT1 agonists or antagonists)
RN 247157-70-6 USPATFULL
CN Benzamide, 3,4-dichloro-N-[2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 247157-80-8 USPATFULL
CN Benzamide, N-[2-[2-(1,4-dimethyl-4-piperidinyl)phenyl]ethyl]-4-fluoro- (CA INDEX NAME)



L37 ANSWER 17 OF 28 USPATFULL on STN
AN 2002:55075 USPATFULL
TI Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
IN Priepke, Henning, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Hauel, Norbert, Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF
Thomas, Leo, Biberach, GERMANY, FEDERAL REPUBLIC OF
Mark, Michael, Biberach, GERMANY, FEDERAL REPUBLIC OF
Dahmann, Georg, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
PI US-20020032238 A1 20020314 <--
AI 2001US-000899884 A1 20010706 (9) <--
PRAI 2000DE-DE10033337 20000708 <--
2000US-000220115P 20000724 (60) <--
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to substituted piperazine derivatives of general formula ##STR1##

wherein

R.sup.1 to R.sup.7 are defined herein, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 389601-48-3P
(preparation of biphenylcarboxylamides as inhibitors of microsomal triglyceride transfer protein)
RN 389601-48-3 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[[4-(1-piperidinyl)phenyl]methyl]amino]carbonyl]phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



L37 ANSWER 18 OF 28 USPATFULL on STN
AN 2002:22516 USPATFULL
TI Novel substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., North Wales, PA, UNITED STATES
PI US-20020013352 A1 20020131 <--
US------6511980 B2 20030128
AI 2001US-000829767 A1 20010410 (9) <--
PRAI 2000US-0002021319P 20000505 (60) <--
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3200
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPATFULL
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 19 OF 28 USPATFULL on STN
AN 2001:215076 USPATFULL
TI N-acyl and N-aroyl aralkylamides
IN Howard, Harry R., Bristol, CT, United States
PA Pfizer INC, New York, NY, United States (U.S. corporation)
PI US-----6323229 B1 20011127 <--
AI 1999US-000291454 19990414 (9) <--
PRAI 1998US-000081970P 19980416 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1##

wherein m, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X are as defined, useful in treating or preventing migraine, depression and other disorders for which a 5-HT.sub.1 agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 247157-70-6P 247157-80-8P
(preparation of N-acyl and N-aroyl aralkyl amides as 5-HT1 agonists or antagonists)
RN 247157-70-6 USPATFULL
CN Benzamide, 3,4-dichloro-N-[2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 247157-80-8 USPATFULL
CN Benzamide, N-[2-[2-(1,4-dimethyl-4-piperidinyl)phenyl]ethyl]-4-fluoro- (CA INDEX NAME)



L37 ANSWER 20 OF 28 USPATFULL on STN
AN 2001:33270 USPATFULL
TI N-acyl and N-aroyl aralkyl amides as serotonergic agents
IN Howard, Harry R., Bristol, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US------6197773 B1 20010306 <--
AI 2000US-000584680 20000531 (9) <--
RLI Division of Ser. No. 1999US-000291454, filed on 14 Apr 1999
PRAI 1998US-000081970P 19980416 (60) <--
DT Utility
FS Granted
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1##

wherein m, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT.sub.1 agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 247157-70-6P 247157-80-8P
(preparation of N-acyl and N-aroyl aralkyl amides as 5-HT1 agonists or antagonists)
RN 247157-70-6 USPATFULL
CN Benzamide, 3,4-dichloro-N-[2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 247157-80-8 USPATFULL
CN Benzamide, N-[2-[2-(1,4-dimethyl-4-piperidinyl)phenyl]ethyl]-4-fluoro- (CA INDEX NAME)



L37 ANSWER 21 OF 28 USPATFULL on STN (Continued)



IT 188863-69-6P 188863-71-0P
(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)
RN 188863-69-6 USPATFULL
CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-71-0 USPATFULL
CN Benzamide, N-[[4-[(3R,4R)-3-[(4-hydroxy-2-naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 21 OF 28 USPATFULL on STN
AN 2000:157575 USPATFULL
TI Piperidine derivative having renin inhibiting activity
IN Binggeli, Alfred, Fluh, Switzerland
Breu, Volker, Schliengen, Germany, Federal Republic of
Bur, Daniel, Basel, Switzerland
Fischli, Walter, Allschwil, Switzerland
Guller, Rolf, Rheinfelden, Switzerland
Hirth, Georges, Huningue, France
Marki, Hans-Peter, Basel, Switzerland
Muller, Marcel, Frenkendorf, Switzerland
Oefner, Christian, Freiburg, Germany, Federal Republic of
Stadler, Heinz, Rheinfelden, Switzerland
Vieira, Eric, Basel, Switzerland
Wilhelm, Maurice, Morschwiller le Bas, France
Wostl, Wolfgang, Grenzach-Wyhlen, Germany, Federal Republic of
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US------6150526 20001121 <--
AI 1999US-000456283 19991207 (9) <--
RLI Continuation of Ser. No. 1999US-000255185, filed on 22 Feb 1999 which is a division of Ser. No. 1996US-000711339, filed on 6 Sep 1996, now abandoned
PRAI 1995CH-000002548 19950907 <--
1996CH-000001876 19960726 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP Johnston, George W., Epstein, William H., Parise, John P.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 188863-75-4P 188863-77-6P
(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)
RN 188863-75-4 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-77-6 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[[2-(trimethylsilyl]ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L37 ANSWER 22 OF 28 USPATFULL on STN
AN 2000:47369 USPATFULL
TI Piperidine derivatives having renin inhibiting activity
IN Binggeli, Alfred, Fluh, Switzerland
Breu, Volker, Schliengen, Germany, Federal Republic of
Bur, Daniel, Basel, Switzerland
Fischli, Walter, Allschwil, Switzerland
Guller, Rolf, Rheinfelden, Switzerland
Hirth, Georges, Huningue, France
Marki, Hans-Peter, Basel, Switzerland
Muller, Marcel, Frenkendorf, Switzerland
Oefner, Christian, Freiburg, Germany, Federal Republic of
Stadler, Heinz, Rheinfelden, Switzerland
Vieira, Eric, Basel, Switzerland
Wilhelm, Maurice, Morschwiller le Bas, France
Wostl, Wolfgang, Grenzach-Wyhlen, Germany, Federal Republic of
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US------6051712 20000418 <--
AI 1999US-000255185 19990222 (9) <--
RLI Division of Ser. No. 1996US-000711339, filed on 6 Sep 1996
PRAI 1995CH-000002548 19950907 <--
1996CH-000001876 19960726 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP Johnston, George W., Epstein, William H., Parise, John P.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the novel piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 188863-75-4P 188863-77-6P
(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)
RN 188863-75-4 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[4-[[(4-methoxybenzoyl)amino]methyl]phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-77-6 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[4-[(benzoylamino)methyl]phenyl]-3-[[4-[[2-(trimethylsilyl]ethoxy]methoxy]-2-naphthalenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L37 ANSWER 22 OF 28 USPATFULL on STN (Continued)



IT 188863-69-6P 188863-71-0P
(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)
RN 188863-69-6 USPATFULL
CN Benzamide, 4-methoxy-N-[[4-[(3R,4R)-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188863-71-0 USPATFULL
CN Benzamide, N-[[4-[(3R,4R)-3-[(4-hydroxy-2-naphthalenyl)methoxy]-4-piperidinyl]phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 23 OF 28 USPATFULL on STN

AN 95:112535 USPATFULL
TI Amino-substituted benzenesulfonylureas and -thioureas and their use as pharmaceuticals
IN Englert, Heinrich, Hofheim, Germany, Federal Republic of
Mania, Dieter, Konigstein, Germany, Federal Republic of
Hartung, Jens, Hochberg, Germany, Federal Republic of
Gogelein, Heinz, Frankfurt, Germany, Federal Republic of
Kaiser, Joachim, Frankfurt, Germany, Federal Republic of
PA Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)
PI US-----5476850 19951219 <--
AI 1994US-000353263 19941205 (8) <--
PRAI 1993DE-004341655 19931207 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are described amino-substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## The compounds I are used for the treatment of cardiac arrhythmias and for the prevention of sudden heart death caused by arrhythmias and can therefore be used as antiarrhythmics. They are particularly suitable for those cases in which arrhythmias are a result of constriction of a coronary vessel, such as in angina pectoris or in acute cardiac infarct.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 169195-72-6P
(preparation of amino-substituted benzenesulfonurea and -thiourea cardiovascular agents)
RN 169195-72-6 USPATFULL
CN Benzamide, 5-chloro-2-methoxy-N-[2-[3-[[[(methylamino)thioxomethyl]amino]sulfonyl]-4-(1-piperidinyl)phenyl]ethyl]- (CA INDEX NAME)



IT 169195-76-0P
(preparation of amino-substituted benzenesulfonurea and -thiourea cardiovascular agents from)
RN 169195-76-0 USPATFULL
CN Benzamide, N-[2-[3-(aminosulfonyl)-4-(1-piperidinyl)phenyl]ethyl]-5-chloro-2-methoxy- (CA INDEX NAME)



L37 ANSWER 23 OF 28 USPATFULL on STN (Continued)

L37 ANSWER 24 OF 28 USPAT2 on STN
AN 2006:215585 USPAT2
TI Substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., Noth Wales, PA, UNITED STATES
PA Ortho-McNeil Pharmaceutical, Inc., rartan, NJ, UNITED STATES (U.S. corporation)
PI US-----7166601 B2 20070123
AI 2006US-000386960 20060426 (11)
RLI Division of Ser. No. 2005US-000066202, filed on 25 Feb 2005, PENDING Division of Ser. No. 2002US-000291133, filed on 8 Nov 2002, Pat. No. US-----6967199 Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, Pat. No. US-----6511980
PRAI 2000US-0002021311P 20000505 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shameem, Golam M. M.
LREP Coletti, Ellen Ciambrone, Shen, Evelyn D., McKown, Jeremy K.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula

##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPAT2
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 25 OF 28 USPAT2 on STN
AN 2005:171835 USPAT2
TI Substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., Noth Wales, PA, UNITED STATES
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, UNITED STATES (U.S. corporation)
PI US-----7112586 B2 20060926
AI 2005US-000066202 20050225 (11)
RLI Division of Ser. No. 2002US-000291133, filed on 8 Nov 2002, PENDING Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, Pat. No. US-----6511980
PRAI 2000US-000202131P 20000505 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shameem, Golam M. M.
LREP Coletti, Ellen, Shen, Evelyn D., McKown, Jeremy K.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula

##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPAT2
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 26 OF 28 USPAT2 on STN
AN 2003:319310 USPAT2
TI Cyclohexyl derivatives and their use as therapeutic agents
IN Castro Pineiro, Jose Luis, Bishops Stortford, UNITED KINGDOM
Dinnell, Kevin, Much Hadham, UNITED KINGDOM
Elliot, Jason Matthew, Felsted, UNITED KINGDOM
Hollingworth, Gregory John, Brentwood, UNITED KINGDOM
Shaw, Duncan Edward, Bishops Stortford, UNITED KINGDOM
Swain, Christopher John, Duxford, UNITED KINGDOM
Yang, Lihu, Edison, NJ, UNITED STATES
PA Merck Sharp & Dohme Limited, Hertfordshire, UNITED KINGDOM (non-U.S. corporation)
Merck & Co., Inc., Rahway, NJ, UNITED STATES (U.S. corporation)
PI US-----6953792 B2 20051011
WO--2001087866 20011122 <--
AI 2002US-000276129 20010516 (10) <--
2001WO-GB002136 20010516 <--
20021113 PCT 371 date
PRAI 2000GB-000012214 20000519 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saeed, Kamal A.
LREP Panzer, Curtis C., Rose, David L.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 4580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R?17, R.sup.18, R.sup.19, R.sup.21a and R.sup.21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. ##STR1## ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 374821-73-5P
(preparation of cyclohexane derivs. for therapeutic use in the treatment of disorders, such as depression, anxiety, pain, inflammation, migraine, and vomiting)
RN 374821-73-5 USPAT2
CN Benzamide, N-[[trans-4-[4-(4-fluorophenyl)-1-piperidinyl]-1-phenylcyclohexyl]methyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 27 OF 28 USPAT2 on STN
AN 2003:289147 USPAT2
TI Substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, UNITED STATES
Rivero, Ralph A., North Wales, PA, UNITED STATES
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, UNITED STATES (U.S. corporation)
PI US-----6967199 B2 20051122
AI 2002US-000291133 20021108 (10) <--
RLI Division of Ser. No. 2001US-000829767, filed on 10 Apr 2001, Pat. No. US-----6511980
PRAI 2000US-000202131P 20000505 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shameem, Golam M M
LREP Ciambrone Coletti, Ellen, Shen, Evelyn D., McKown, Jeremy K.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPAT2
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L37 ANSWER 28 OF 28 USPAT2 on STN
AN 2002:22516 USPAT2
TI Substituted diamine derivatives useful as motilin antagonists
IN Johnson, Sigmond G., Flemington, NJ, United States
Rivero, Ralph A., North Wales, PA, United States
PA Ortho McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)
PI US-----6511980 B2 20030128 <--
AI 2001US-000829767 20010410 (9) <--
PRAI 2000US-000202131P 20000505 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Small, Andrea D.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel substituted diamine derivatives for the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2, X.sup.3, X.sup.4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 373805-43-7P
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373805-43-7 USPAT2
CN Benzamide, N-[[(1R,3S)-3-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)cyclohexyl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



```
=> d his


     (FILE 'HOME' ENTERED AT 14:08:18 ON 12 MAY 2008)

     FILE 'HCAPLUS' ENTERED AT 14:08:31 ON 12 MAY 2008
L1             1 US20070043079 /PN

     FILE 'REGISTRY' ENTERED AT 14:11:32 ON 12 MAY 2008

     FILE 'HCAPLUS' ENTERED AT 14:11:36 ON 12 MAY 2008
L2             TRA L1 1- RN :      303 TERMS

     FILE 'REGISTRY' ENTERED AT 14:11:36 ON 12 MAY 2008
L3           303 SEA L2
L4           213 L3 AND NC5/ES
L5           207 L4 AND >=2 46.150.18/RID
L6           175 C28H31CLN2O3
L7            28 L6 AND NC5/ES
L8            28 L7 AND 46.150.18/RID
L9            13 L8 AND 4 CHLORO
L10              STR
L11            1 L10
L12       408602 >=2 46.150.18/RID AND 46.156.1/RID
L13          166 L12 AND L3
L14              STR L10
L15           14 L14 SAM SUB=L12
L16          860 L14 FULL SUB=L12
                 DEL J704C1/A
                 SAV TEM L16 J704C1/A
L17          129 L16 AND L3
L18          731 L16 NOT L17

     FILE 'HCAPLUS' ENTERED AT 15:21:33 ON 12 MAY 2008
L19            1 L17
L20           34 L18
L21           24 L20 AND (PD<=20040416 OR AD<=20040416 OR PRD<=20040416)
L22           22 L20 AND (PD<=20030418 OR AD<=20030418 OR PRD<=20030418)
L23           20 L20 AND PD<=20030416
L24           16 L20 AND PD<=20020418
L25           24 L21-24
L26           10 L20 NOT L25

     FILE 'HCAOLD' ENTERED AT 15:25:06 ON 12 MAY 2008
L27            0 L17
L28            1 L18
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:25:29 ON 12 MAY 2008
L29            1 E1

     FILE 'HCAPLUS' ENTERED AT 15:28:28 ON 12 MAY 2008
                 SEL HIT RN L25

     FILE 'REGISTRY' ENTERED AT 15:29:21 ON 12 MAY 2008
L30           70 E2-71

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 15:35:55 ON 12 MAY 2008
L31            2 L17
L32           29 L18
L33           28 L32 AND (PD<=20040416 OR AD<=20040416 OR PRD<=20040416)
L34           25 L32 AND (PD<=20030418 OR AD<=20030418 OR PRD<=20030418)
L35           12 L32 AND PD<=20030416
L36            9 L32 AND PD<=20020418
L37           28 L33-36

     FILE 'REGISTRY' ENTERED AT 15:44:08 ON 12 MAY 2008
L38            6 L6 AND L16
```

```
     FILE 'HCAPLUS' ENTERED AT 15:44:28 ON 12 MAY 2008
L39           1 L38

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 15:45:52 ON 12 MAY 2008
L40           2 L38

=>
```